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ABSTRACT 
Sarcoidosis is a granulomatous multisystem disorder of unknown aetiology, 
primarily manifesting in the lungs. The disease appears in two forms, which are 
mainly distinguished based on clinical criteria; Löfgren’s syndrome (LS) presents 
with acute onset, usually fever, active inflammation and characteristic symptoms 
such as bilateral hilar lymphadenopathy (BHL), erythema nodosum and/or ankle 
arthritis, but is also associated with spontaneous resolution and a good prognosis. 
In contrast, “non-LS” comprises a more heterogeneous patient group, with 
common characteristics being an insidious onset, slower disease progression and a 
higher risk of developing chronic disease, extrapulmonary manifestations and 
eventually pulmonary fibrosis. Despite advances in genetics, epidemiology, 
immunology and therapeutics during the past decades, the disease-triggering 
antigen(s) and the immunological mechanisms underlying different clinical 
phenotypes remain a “blind spot” – something that is known to exist but that the 
eye is, as yet, unable to perceive. Previous studies have shown the human 
leukocyte antigen (HLA)-DR allele HLA-DRB1*03 to associate closely with LS and a 
favourable clinical outcome. In these patients, local expansion of CD4+ T cells 
carrying the specific T cell receptor (TCR) variable (V) segment Vα2.3 in the lungs 
suggests specific antigen recognition, making these cells ideal tools in the quest 
for disease-triggering factors in sarcoidosis. 
 
The aims of this thesis were therefore to investigate on one hand the phenotype, 
functionality and ultimately antigen-specificity of TCR-specific CD4+ T cells, and 
on the other to improve understanding of immunological mechanisms underlying 
distinct clinical phenotypes of sarcoidosis. 
 
In HLA-DRB1*03+ patients with sarcoidosis, Vα2.3 was found to preferentially pair 
with the Vβ22 TCR segment on CD4+ T cells in the lung. Expression of activation 
markers on these cells indicated an advanced state of differentiation, consistent 
with prolonged antigen exposure, and a high degree of clonality, marked by 
appearance of identical and near-identical TCR α and β CDR3 sequences between 
patients. In addition, molecular modelling of the TCR Vα2.3/Vβ22-HLA-DRB1*03 
complex revealed an ideal fit into the peptide-binding cleft of a peptide derived 
from the carboxyl (C)-terminal of cytoskeletal protein vimentin, implicating 
vimentin as a potential (auto)antigen in sarcoidosis and suggesting especially LS 
to harbour traits of autoimmunity. Accordingly, anti-vimentin IgG and IgA 
antibodies were detected in the lungs of sarcoidosis patients to a higher degree 
than in healthy individuals, and correlated with expression of the Vα2.3/Vβ22 
TCR. HLA-DRB1*03+ patients also demonstrated lower total Ig counts, but 
stronger reactivity towards the vimentin C-terminal, ultimately suggesting a more 
antigen-driven, but less aggressive, cooperative T-B cell response in HLA-
DRB1*03-mediated disease. 
 
Particularly in LS patients, CD4+ T cells in the lung demonstrated simultaneous 
expression of T helper (TH) 1 transcriptional regulator T-bet and TH17 counterpart 
RORγT, which intriguingly correlated with non-chronic disease, and responded to 
stimuli with a broad array of cytokines, including interleukin (IL)-10, IL-2, IL-17A 
and IL-22, in addition to interferon (IFN)-γ, the main cytokine produced in non-LS 
patients. Moreover, expression of inhibitory receptors CTLA-4 and PD-1 indicated 
a higher degree of regulatory capacity compared to non-LS CD4+ T cells, where 
elevated expression of HLA-DR, CD127 and CD39 pointed towards a more 
pronounced effector profile. The discovery of marked CD8+ T cell proliferation in 
both patient groups provides further evidence for a hitherto unappreciated role of 
CD4+ T cells in restriction of cytotoxic T cell activity to prevent tissue damage in 
sarcoidosis, with loss of CTLA-4- and PD-1-mediated inhibition in non-LS patients 
exacerbating the risk of developing chronic disease and permanent scarring. 
Combined with reduced expression of adhesion marker CD44 in LS, this detailed 
characterisation outlines a possible mechanism for spontaneous resolution of 
granulomas. 
 
The collected findings of this thesis suggest fundamental differences in CD4+ T cell 
biology that may be of key importance for disease resolution and progression, 
respectively, in clinical phenotypes of pulmonary sarcoidosis. Moreover, the 
results presented constitute an important step forward in the search for disease-
specific antigens, and provide incentive for further exploration of sarcoidosis, and 
LS in particular, as an autoimmune condition, at least partly driven by cognate T 
and B cell reactivity to vimentin. Hopefully, these discoveries may shed further 
light upon the still-elusive enigma of sarcoidosis, act as a foundation for 
continued investigation of disease-instigating factors, and ultimately contribute 
to reconsideration of current disease classification. 
  
  
POPULAR SCIENCE SUMMARY 
The Blind Spot concerns sarcoidosis, which is an inflammatory lung disease of 
unknown origin. It can also affect several other organs, such as the spleen, liver, 
kidneys, skin, eyes, or, most severely, the heart or central nervous system (CNS). 
Disease occurrence varies with geographical region, but is particularly high in 
Northern Europe; the annual incidence in Sweden is approximately 1200, with 
around 16,000 individuals currently being estimated to suffer from sarcoidosis. 
However, symptomatic presentation is highly variable, and many cases likely 
remain unresolved. Sarcoidosis presents in two main forms, both of which are 
characterised by the presence of so-called granulomas, large collections of 
immune cells, in the affected organs. In addition, an expansion of T cells, a branch 
of the adaptive immune system, is observed in the lungs and used as a diagnostic 
determinant. Löfgren’s syndrome (LS) is an acute condition characterised by fever, 
enlarged lymph nodes and marked inflammatory reactions on the lower 
extremities. “Non-LS” comprises a much more diverse group, with patients usually 
experiencing insidious onset, slower progression, and a higher frequency of 
symptomatic manifestation from other organs than the lungs. Importantly, 
patients with LS usually have a good prognosis, with the disease resolving 
spontaneously within a few months up to two years. In contrast, non-LS patients 
have a higher risk of developing chronic disease with permanent tissue damage 
and eventually pulmonary fibrosis, which, together with cardiac and CNS 
involvement, are the most common causes of sarcoidosis-associated mortality. As 
yet, therapeutic options are limited and remain unspecific, and most patients 
receive either no treatment, or merely symptomatic relief, for their disease. 
 
Previous studies have shown the two conditions to differ markedly in genetic 
background, with genes governing uptake and recognition of immune-stimulatory 
substances, so-called antigens, deviating substantially between LS and non-LS. 
Specifically, presence of genetic variant HLA-DRB1*03 is closely linked to LS and a 
good prognosis. HLA molecules are responsible for presentation of protein-derived 
segments, or peptides, to T cells for recognition and subsequent activation. 
However, the exact immunological pathways underlying the two disease 
conditions remain unknown, a “blind spot”, as do the identity of the disease-
triggering substance(s). The aim was therefore to conduct a search for disease-
specific antigens, as well as to perform a detailed investigation of T cell responses 
in the lungs of sarcoidosis patients, ultimately striving to identify factors that 
affect disease resolution or progression in LS and non-LS patients, respectively. 
 The results presented in this thesis show an increase of T cells expressing a 
particular T cell receptor (TCR) for antigen recognition in the lungs of sarcoidosis 
patients positive for HLA-DRB1*03. These cells express markers associated with T 
cell maturation and exposure to antigenic stimulation, suggesting that these cells 
could be used as tools for antigen discovery. Using the previously known structure 
of the HLA-DRB1*03 molecule and the newly identified TCR, a molecular model 
was generated to identify structural characteristics of the presented antigenic 
peptide. This approach indicated that vimentin, a protein participating in 
maintenance of the cellular cytoskeleton, could be a candidate antigen in 
sarcoidosis, thereby suggesting the disease to have traits of autoimmunity. Further 
studies revealed reactivity not only of T cells, but also of B cells, which are 
responsible for antibody production, towards vimentin. This reactivity was 
specifically localised to the lung and most prominent in HLA-DRB1*03+ patients. 
 
Overall, these studies demonstrate several notable differences in T cell biology 
between LS and non-LS patients. Most prominently, T cells from LS patients 
exhibited a more diverse functional repertoire, maintaining both activating and 
inhibitory functions. An efficient, but self-restrictive immune response could be 
related to both the acute disease onset and spontaneous resolution observed in 
this patient group. In contrast, non-LS patients showed signs of a more destructive 
immune reactivity, possibly contributing to propagated inflammation that may 
result in chronic disease, tissue destruction and eventually fibrotic scarring. It is 
possible that, in time, these two conditions will come to be considered as separate 
disease entities. 
 
In conclusion, this thesis provides further insights into complex immunological 
mechanisms in the lungs of sarcoidosis patients, and identifies factors related to 
antigen recognition and immune regulation as particularly important in the 
development of LS or non-LS disease, respectively. Enhanced understanding of 
subtle molecular differences between the two conditions may contribute to 
improved prognostic assessment in a clinical setting, as well as advances in future, 
more targeted therapeutic strategies. Most prominently, the identification of TCR-
specific T cells in HLA-DRB1*03+ LS patients provides a theoretical and 
methodological foundation for further investigation of disease origin, both in LS 
and non-LS, with the aim of resolving the “blind spot” of sarcoidosis. 
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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
The human immune system is a complex network of defence mechanisms that act 
in conjunction to protect the host from disease. It involves specialised immune 
cells that target harmful, foreign substances for destruction, as well as peripheral 
organs and tissue barriers that prevent the entry of invading microbes. Divided 
into two major branches, the innate and the adaptive, the immune system ensures 
both rapid responsiveness, as well as gradual development of a highly efficient and 
targeted elimination of pathogens (Fig. 1). 
 
Innate, or natural, immunity constitutes the inherent protective mechanism that 
guards the body against microbial invasion. The first line of defence is comprised 
of physical barriers at mucosal surfaces such as the skin, respiratory and 
gastrointestinal tracts, where cells and natural antibiotics in the epithelium block 
the entry of foreign substances. If the epithelial layer is breached, the presence of 
microbes in the tissue or circulation will alert phagocytic cells, most prominently 
tissue-resident macrophages, neutrophils and circulating monocytes. Innate 
immune cells react rapidly (within hours) to common microbial structures, termed 
pathogen-associated molecular patterns (PAMPs), or damage-associated 
components released by necrotic cells (DAMPs), ensuring responsiveness to a 
broad range of possible detrimental agents. Engagement of membrane-bound 
pattern-recognition receptors (PRRs) results in downstream activation of 
transcription factors promoting upregulation of endothelial adhesion molecules 
and release of extracellular signalling mediators, including cytokines such as 
interleukin (IL)-1β, IL-6, IL-12, IL-18, tumour necrosis factor (TNF)-α and 
chemokines for recruitment of cells to the site of inflammation. Upon activation, 
natural killer (NK) cells, a distinct set of bone marrow-derived lymphocytes, 
mediate lysis of infected cells and secretion of interferon (IFN)-γ, a cytokine 
essential for driving macrophage activation, engulfment and destruction of 
microorganisms. Finally, dendritic cells (DCs) and other antigen-presenting cells 
(APCs), are essential in orchestrating the induction of adaptive immune responses 
through the efficient uptake, processing and presentation of foreign antigens, as 
well as secretion of cytokines that promote differentiation of effector cells (1). 
 
Adaptive, or acquired, immunity is mediated by lymphocytes, most prominently T 
and B cells. In contrast to innate immune cells, lymphocytic responses emerge 
  2 
later (within days) following the initial triggering event, but somatic 
recombination of germline-encoded receptor gene segments allows for superior 
diversity and enhanced specificity of responses to antigen. The low number of cells 
with a particular antigen specificity, in combination with the high variability in 
receptor composition, generates an extremely diverse cellular repertoire that is 
able to respond to a vast number and variety of antigens. As opposed to innate 
immune cells, this reactivity may also include non-infectious agents as well as 
microbes, and, in some instances, even self-antigens. Following recognition of an 
antigen presented on an APC, mature activated lymphocytes undergo clonal 
expansion to generate multiple progeny cells with the same antigen specificity. 
Elimination of the antigenic source by effector cells, and thereby removal of 
stimuli essential for effector cell survival, eventually results in apoptosis of the 
majority of clonally expanded cells, allowing the immune system to resume 
homeostasis after antigen clearance. The residual fraction of effector cells remain 
in the form of long-lived memory cells that are able to mount rapid and specific 
recall responses to previously encountered pathogens, enabling targeted and 
efficient clearance of antigen upon re-infection (1, 2). 
 
 
 
 
Figure 1 | Major components of the human immune system. The innate and adaptive branches 
of the immune system together orchestrate a coordinated cascade that ensures both rapid 
responsiveness to common pathogenic patterns, as well as highly efficient, antigen-specific 
cellular and humoral responses that ultimately result in elimination of the antigenic source and 
generation of long-lived memory cells. The figure offers a schematic overview of cell types, 
receptors and secreted signalling mediators central to innate and adaptive immunity. 
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1.2 T LYMPHOCYTES 
T cells, which constitute the cellular branch of the adaptive immune system, 
develop in the bone marrow and migrate to the thymus for maturation. All T cells 
are equipped with a T cell receptor (TCR) designed and selected for recognition of 
peptide antigens derived from foreign, potentially harmful protein structures, e.g. 
bacteria, viruses and parasites. Naïve T cells continuously circulate through 
secondary lymphoid organs in search for antigen, which, when recognised, will 
result in their activation and differentiation into effector cells. These cells then 
migrate to peripheral sites to perform effector functions, e.g. initiation of antibody 
production by B cells and priming of macrophage activity. Cells carrying the 
cluster of differentiation (CD) 4 co-receptor on their surface are termed T helper 
(TH) cells, and serve to orchestrate the immune response through activation of B 
cells, phagocytic cells, and cytotoxic CD8+ T cells. These functions are mediated 
both through direct cell-cell interactions and release of cytokines and chemokines. 
CD4+ T cells recognise protein antigens presented on human leukocyte antigen 
(HLA) class II molecules on the surface of APCs such as DCs, macrophages and B 
cells (3). CD8+ T cells, also termed cytotoxic T lymphocytes (CTLs), instead 
respond to HLA class I-presented peptides and frequently require concomitant 
activation of CD4+ T cells and their subsequent secretion of stimulatory cytokines. 
Activation of CTLs results in granule exocytosis, and the release of perforin and 
granzymes into the extracellular space. Perforin inserts into the cell membrane to 
form pores that facilitate entry of granzymes, which in turn engage the apoptotic 
cascade, directly killing the infected, antigen-expressing target cell. 
 
1.3 HLA IN IMMUNITY AND DISEASE 
HLA class I molecules are expressed on all nucleated cells and accommodate 
peptides averaging 8-11 amino acids in length, which they present to CD8+ T cells. 
These antigens are often derived from cytosolic proteins synthesised within the 
cells, e.g. viral proteins. Class II molecules are expressed on the surface of 
professional APCs and comprise five main binding pockets at positions P1, P4, P6, 
P7 and P9, which bind peptides of 13-15 amino acid residues with broad 
specificity, i.e. not all peptide-binding pockets have to be occupied in order for a 
peptide to be recognised (4). These peptides are usually internalised from the 
extracellular environment and are presented to CD4+ T cells. In addition, the 
process of cross-presentation, which occurs e.g. when an APC has ingested an 
infected cell, allows peptides derived from the same intracellular protein to be 
presented both on class I molecules to CD8+ T cells and on class II molecules for 
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recognition by CD4+ T cells. HLA molecules present only one peptide at a time, but 
each molecule is capable of presenting multiple different peptides, as long as the 
binding pockets can accommodate the anchor residues of the peptide. Other 
residues project upward for interaction with and recognition by the TCR (1). 
 
Figure 2 | The HLA genetic region. In humans, the HLA loci are located in the p21.3 section on 
chromosome 6. In addition to the major and minor HLA class I and class II alleles, this region 
comprises HLA class III alleles, which encode, among others, gene products involved in 
transcriptional regulation, immune activity, protein-protein interactions, transport and signalling, 
as well as serum protein mediators and TNF family cytokines. 
 
In humans, the HLA loci are located on chromosome 6 and comprise HLA-A, -B, 
and –C (class I) as well as HLA-DP, -DQ and -DR (class II) alleles. In addition, 
minor class I alleles HLA-E, -F and -G and HLA class II alleles HLA-DM and -DO, 
associated with internal antigen processing, are also encompassed in the same 
genetic region (Fig. 2). Each individual inherits one maternal and one paternal 
copy of the same HLA allele. Hence, for HLA class I, which exists in three major 
forms, any given cell can express six different class I molecules. For class II, every 
individual inherits one pair of HLA-DP genes (DPA1 and DPB1, for the α and β 
chains, respectively), one pair of HLA-DQ (DQA1 and DQB1), one HLA-DRα 
(DRA1) and one or two HLA-DRβ genes (DRB1 and DRB3, -4 or -5) from each 
parent. The DR β chain is encoded by four different loci, but no more than three 
functional loci are present in any given individual. HLA-DRB1 genes encode a 
large number of functionally variable products, while HLA-DRB3, HLA-DRB4 and 
HLA-DRB5 show decreasing variability and are tightly associated with presence of 
certain DRB1 alleles (5, 6). Distinct DR and DQ alleles are in so-called linkage 
disequilibrium, meaning that they are frequently inherited together, and the HLA 
class I and II alleles present on each chromosome together constitute the genetic 
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haplotype. The numerous possibilities for combination inherent to each individual 
and the highly polymorphic spread of HLA alleles ensure that some members of an 
outbred population will always be able to present, recognise and mount an 
immune response to any particular pathogen (1). 
 
1.4 ANTIGEN PRESENTATION 
The distinction between HLA class I and class II molecules and the range of cells 
expressing a respective class of molecules ensure that the immune response 
mounted is ideally suited to manage the current threat. For extracellular antigens, 
this specifically involves activation of CD4+ T cells that in turn promote antibody 
production by B cells and activation of phagocytosis by macrophages. In contrast, 
CTL-mediated direct lysis of peptide-presenting infected cells is a more efficient 
strategy in the case of antigens present in the cytosol. 
 
Antigen processing follows two main pathways depending on the route of uptake. 
Degradation of cytosolic proteins by the proteasome is followed by loading onto 
the membrane-bound protein transporter associated with antigen processing 
(TAP) in the endoplasmic reticulum (ER), where HLA molecules are being 
synthesised. TAP facilitates transport of peptides into the ER, and by linkage to 
the protein tapasin, which attaches to newly synthesised HLA class I molecules, 
the empty HLA molecules are poised to receive peptides entering the ER. Loading 
of a peptide stabilises the complex and triggers release from TAP, whereupon the 
peptide-class I complex can be transported to the cell surface through exocytosis. 
For presentation of extracellular peptides ingested by APCs, proteins are degraded 
under the acidic conditions of the endosomal and lysosomal compartments. HLA 
class II molecules produced in the ER carry an invariant chain, where the section 
termed the class II-associated invariant chain peptide (CLIP) attaches tightly to 
the peptide-binding cleft. The occupation of the peptide groove by CLIP ensures 
that intracellular peptides transported into the ER by TAP can bind their intended 
class I molecules, and are not accidentally paired with class II. Instead, CLIP-
bound class II molecules are dispatched in exocytic vesicles that eventually fuse 
with the late endosomal-lysosomal vesicles containing proteolytically degraded 
extracellular peptides. There, the DM protein mediates exchange of CLIP for 
surrounding higher-affinity peptides, binding of which stabilises the class II 
complex and enables its transport to the cell surface. Failure of peptide 
recognition results in degradation of empty molecules by vesicular proteases.  
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Importantly, a single protein may give rise to many different peptides, only a few 
of which are bound by the HLA; these peptides are referred to as 
immunodominant, as solely the HLA-bound peptides are able to initiate immune 
responses by T cells. The HLA combination in any given individual thus 
determines which peptides can be presented, and consequently the ability of that 
person to mount an immune response to a certain antigen. Once bound, peptides 
remain in the binding-cleft up to several days, increasing the possibility that a T 
cell specific for the presented peptide will recognise it. Engagement of the TCR in 
response to an HLA molecule and its peptide sustains surface expression of the 
complex, allowing downstream signalling through the TCR to occur (1, 7). 
 
1.5 TCR SIGNALLING 
Antigen recognition is mediated through several steps, the first of which being the 
recognition by a TCR of a peptide epitope for which it is specific. Most commonly, 
TCRs consist of an α and a β chain, each of which contain a constant and a variable 
domain. The α chain variable region is encoded by variable (V) and joining (J) gene 
segments; for the β chain, these are interspersed with additional diversity (D) 
segments. Somatic rearrangement of the germline repertoire and additional 
random nucleotide insertions and deletions between the V, D and J segments then 
facilitate the immense variability in TCR specificity that is required for recognition 
of a broad range of pathogens. The antigen-binding site itself comprises three 
complementarity determining regions (CDRs), of which CDR3 is the most variable 
and also the major contact point for antigen recognition. Signal transduction 
through the TCR into the cell also requires T cell-specific co-receptor CD3 and the ζ chain, which jointly generate an activation signal upon TCR recognition of HLA-
peptide complexes (Fig. 3). Most TCRs bind the peptide-HLA complex with low 
affinity, and upon TCR binding, chemoattractant molecules are released to 
promote association of T cell integrin leukocyte function-associated antigen-1 
(LFA-1) with its APC-bound ligand intercellular adhesion molecule-1 (ICAM-1). 
This mediates stable cellular adhesion and proximity for a prolonged period of 
time, allowing receptor and co-receptor engagement to yield a productive 
response. The T cell CD4 and CD8 co-receptors ensure accurate binding of the TCR 
to either HLA class II or class I molecules, respectively. The second signal of 
activation is then mediated by co-stimulatory molecules on the surface of the T 
cell and APC, namely interaction of activating co-receptor CD28 and CD40L on the 
T cell with CD80/CD86 and CD40, respectively, on the APC. This chain of events 
induces phosphorylation, docking and activation of downstream intracellular 
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kinases that eventually result in upregulation of adequate transcription factors in 
the nucleus, driving the effector response and subsequent T cell proliferation, 
differentiation, cytokine production, clonal expansion, and finally, cell migration 
to the site of inflammation (1). 
 
 
Figure 3 | Antigen presentation and TCR signalling. Detail of the interface between an APC and 
a CD4+ T cell and the main components and co-receptors involved in antigen presentation and 
subsequent downstream TCR signalling. Successful recognition of an HLA class II-presented 
peptide by the TCR and simultaneous recognition of HLA class II by the CD4 co-receptor trigger an 
intracellular phosphorylation cascade mediated by kinases and adaptor proteins associated with T 
cell co-receptors CD3 and ζ, ultimately resulting in activation of transcription factors involved in 
inflammatory processes. Concomitant association of activating co-receptor CD28 on the T cell with 
its ligands CD80/CD86 on the APC, T cell CD40L and APC CD40, as well as T cell secretion of 
activating cytokines, provide a stimulatory environment for continued interaction and signalling. 
In addition, attachment of integrins LFA-1 and ICAM-1 to one another ensure the immunological 
synapse is maintained. The α and β CDR3 regions of the TCR comprise the most amino acid 
variability and carry the main responsibility for antigen recognition. 
 
1.6 CD4+ T CELL SUBSETS 
Upon activation, CD4+ T cells can differentiate into various subsets with different 
characteristics and functions, the most commonly discussed termed TH1, TH2 and 
TH17, as well as regulatory T cells (TREGs). TH1 cells are characterised by expression 
of transcription factors T-bet, signal transducers and activators of transcription 
(STAT)1 and STAT4, production of cytokines IFNγ, IL-2 and TNF-α, activation of 
macrophages, as well as induction of antibody class-switching in B cells. TH1 
differentiation is induced by IL-12, IL-18 and IFNγ, and constitutes an important 
protective response against intracellular microbes (3, 8, 9). 
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TH2 cells are polarised through IL-4 signalling via STAT6, express transcription 
factor GATA3 and produce IL-4, IL-5 and IL-13 (10), which induce eosinophil 
activation and IgE, IgG1, IgG4 and IgA production by B cells. TH2 cells are major 
mediators of asthma and allergic responses, but also serve a physiological role in 
protection against helminths (3, 11). 
TH17 cells constitute an unstable phenotype that can have both pro-inflammatory 
and immune-dampening, homeostatic functions, depending on the tissue context 
and polarising environment. Transforming growth factor (TGF)-β in conjunction 
with IL-6 contribute to upregulation of transcription factor RORγT, STAT3 and 
TH17 differentiation (12). TH17 cells can produce IL-17A, IL-17F, IL-21 – which 
acts in an autocrine feed-forward manner to stabilise the TH17 phenotype – and 
IL-22. While crucial in the immune response against parasites, TH17 cells are also 
heavily implied in autoimmune diseases such as rheumatoid arthritis (RA) (13, 14), 
psoriasis (15, 16) and multiple sclerosis (MS) (17). It has been demonstrated that in 
the presence of IL-23, the TH17 programme is skewed towards a more pro-
inflammatory, granulocyte-macrophage colony-stimulating factor (GM-CSF)-
producing and potentially harmful phenotype, while absence of IL-23 instead 
fosters a regulatory state and shifts the cytokine profile towards IL-10 and possibly 
IL-26 (18, 19). The balance between these two variants may be, at least in part, 
attributed to the target organ: in the gut and the lung, IL-17 and IL-22 have been 
shown to play a protective role in infectious disease as well as in tissue repair and 
dampening of fibrotic progression (20-22). It is possible that TH17 responses are 
involved in local homeostasis in mucosal organs, while at the same time being 
detrimental at other sites such as the joint, skin or nervous system. 
In addition to the more established subsets, TH22 and TH9 cells have recently been 
described as functionally distinct from TH17 and TH2 cells, respectively; however, 
these remain incompletely characterised. 
 
TREG cells are generally characterised by expression of transcription factor FoxP3, 
and a combination of surface receptors CD25, cytotoxic T lymphocyte-associated 
antigen-4 (CTLA-4), CD39, CD73, programmed cell death protein-1 (PD-1), CD103, 
CD27 and lack of CD127 (23-31). The true definition of a regulatory phenotype, 
however, is based on the cell’s capacity to suppress effector cells, which can occur 
despite lack of several of the above-mentioned markers and differences in FOXP3 
gene methylation status (32, 33). Notably, FoxP3 is also upregulated in effector 
cells undergoing activation (34), and can be expressed in conjunction with other 
transcription factors. Joint T-bet and FoxP3 expression has recently been 
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suggested to be involved in maintaining local tissue homeostasis (35, 36). The 
majority of TREGs develop through high-avidity recognition of self-antigens, and 
subsequently act to prevent tissue damage caused by autoreactive T cells that 
evade negative selection in the thymus. Regulatory cells can also be induced in the 
periphery in response to TCR stimulation in combination with other factors such 
as IL-2 and TGF-β (37). TREGs restrict immune activity both through secretion of 
anti-inflammatory cytokines such as IL-10, IL-35 and TGF-β, as well as through 
direct binding of inhibitory co-receptor CTLA-4 to CD80/CD86 on APCs with 
higher affinity compared to CD28, thereby competing out its co-stimulatory 
effects (38). Dysregulation of TREG function is a common trait in several chronic 
inflammatory disorders (39). 
 
1.7 T CELL PLASTICITY 
Though still frequently used, recent advances in the field of T cell immunology 
and increased understanding of the concept of CD4+ T cell plasticity and 
multifunctionality has brought into question the conventional monolithic 
paradigm of CD4+ T cell lineage commitment and terminal differentiation into 
distinct subsets. Rather than a stable lineage phenotype from which a cell does not 
diverge for the remainder of its lifespan, a cell may over the course of an immune 
response express phenotypic and functional characteristics of several subsets, 
switching between different states depending on the tissue microenvironment, the 
triggering antigen and the disease course.  
Given the diverse nature and uncountable number of microbial pathogens, as well 
as the gradual development of increasing numbers of memory cells that may cause 
inappropriate responses if exposed to new pathogens with similar, but not 
identical, characteristics, it is only reasonable to assume that CD4+ T cells ought 
to, by design, be able to specifically tailor their responses in retort to the threat at 
hand. It is therefore highly plausible that the local cytokine milieu influences CD4+ 
T cell polarisation depending on the need of the host, thus utilising the full 
repertoire of CD4+ T cells to generate a more efficient immune response (40). 
Accordingly, cytokine profiles have been found to be far more flexible than 
formerly understood, with IFNγ being produced by either TH1 or TH17 cells; TH1, 
TH2, TH17 as well as TREGs being able to produce IL-10; IL-9 production by either 
TH2 or TH17 cells; complete loss of IL-17A production by TH17 cells to become sole 
IFNγ producers; and simultaneous production of IL-22 and IFNγ, among others 
(40). Likewise, expression of master transcription factors that are believed to drive 
differentiation programmes is not fixed. In addition to the transient expression of 
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FoxP3 during effector cell activation and localised co-expression of FoxP3 and T-
bet, TREGs may express FoxP3 in conjunction with RORγT, despite the two being 
believed to constitute opposing end points of the same differentiation pathway 
(41, 42). Interestingly, IL-17-producing TREGs are still suppressive (43, 44). Much of 
this instability, or flexibility, can probably be attributed to the migratory patterns 
of CD4+ T cells, whereby irreversible commitment could confer a disadvantage 
under rapidly changing conditions or in diverse tissue microenvironments. A more 
nuanced and accurate view of T cell differentiation may therefore be that of a 
dynamic gradient of transcription factor expression, with CD4+ T cells 
preferentially expressing particular transcriptional regulators but being able to 
adapt to shifts in the microenvironment, or throughout different phases in the life 
of a cell, by up- or downregulating other factors. Rather than an “on-and-off” 
state of transcription factor expression, a more appropriate depiction may be an 
array of different transcription factors, expressed at different ratios relative to one 
another, that ultimately govern the specialised function of CD4+ T cells at a 
particular tissue site and moment in time (40) (Fig. 4). 
 
 
 
Figure 4 | CD4+ T cell plasticity. Schematic outline of documented TH subsets, along with their 
“master” transcriptional regulators and postulated pathways of inter-differentiation. The delicate 
balance of transcription factor expression believed to ultimately dictate cell fate at a certain, 
compartment-specific time point is here represented by green arrows. Rather than entering a state 
of terminal differentiation, the cell is thereby able to respond to various stimuli in its 
microenvironment and adapt its functionality accordingly. 
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1.8 ANTIBODIES 
Antibodies, also termed immunoglobulins (Ig), are Y-shaped proteins that can 
exist either in membrane-bound form as part of the B cell receptor (BCR) complex 
mediating antigen recognition, or secreted, serving to neutralise and eliminate 
microbes and toxins. The general structure of an antibody comprises two identical 
heavy chains and two light chains, each chain containing a variable (V) and a 
constant (C) region. The combined V domains of the heavy and light chains 
together constitute the antigen-binding region, where, similarly to the TCR, three 
CDR loops act as the key site for antigen recognition. In humans, five different 
antibody isotypes exist, distinguished by their structure as well as their effector 
functions: IgM, IgD, IgG, IgA, and IgE. IgM is the first antibody produced and is 
secreted in the form of a pentamer with high avidity, acting to eliminate 
pathogens in the early stages of humoral immunity. Together with IgD, IgM 
constitute the BCR repertoire of naïve B cells. IgD also stimulates basophils and 
mast cells to produce antimicrobial factors (45). IgG is the primary isotype found 
in the circulation and exists in four subclasses, in humans termed IgG1, IgG2, IgG3 
and IgG4, which differ in abundance and sensitivity to various antigenic sources. 
General functions of IgG include opsonisation of foreign antigens for phagocytosis 
by macrophages and neutrophils, neutralisation of microbes and free toxins, and 
promotion of antibody-dependent cellular cytotoxicity by NK cells. In addition, 
maternal IgG is able to transfer across the placenta to mediate neonatal immunity. 
IgG antibodies also provide feedback inhibition to B cells by binding to inhibitory 
receptors. IgA is found primarily in mucosal organs, e.g. the respiratory, 
gastrointestinal and urogenital tracts, as well as in mucous bodily fluids such as 
saliva, tears and breast milk, where it facilitates rapid neutralisation of toxins and 
microbes. Finally, IgE is an essential component of the defence against helminthic 
parasites, but is also responsible for mediating immediate hypersensitivity 
reactions by binding to allergens and triggering mast cell degranulation of 
histamine (1). 
 
1.9 B LYMPHOCYTES 
B cells, effector cells of the humoral branch of the adaptive immune system, 
develop and mature in the bone marrow, undergoing V(D)J recombination of the 
heavy and light BCR chains similarly to their TCR equivalents. Following 
successful receptor assembly, transitional B cells, recognised by a high surface 
expression of IgM and IgD, leave the bone marrow and migrate to the spleen to 
undergo the final stages of maturation. Once mature, their primary effector 
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function is the production of highly specific antibodies, which act to neutralise, or 
otherwise opsonise and target foreign antigens for destruction. Within peripheral 
lymphoid organs, T cells and B cells are localised in separate compartments; at 
homeostasis, B cells reside in distinct structures termed follicles, while T cells are 
dispersed outside but adjacent to the follicles (1). 
 
1.9.1 B cell activation 
As opposed to T cells, which almost exclusively react to peptide antigens, B cells 
recognise conformational as well as linear epitopes derived from a wide range of 
distinct antigenic compounds, including proteins, lipids, polysaccharides, nucleic 
acids and small chemicals. Protein antigens are processed by APCs and recognised 
by T cells, which in turn provide stimulatory signals to B cells to initiate antibody 
production; such antigens are termed “T cell-dependent”. Non-protein antigens 
are able to propagate antibody responses without T cell interaction and are 
therefore called “T cell-independent”. Similarly to T cells, clustering of membrane 
Ig receptors initiates a downstream biochemical signalling cascade ultimately 
resulting in activation of transcription factors responsible for B cell proliferation 
and differentiation. Signal transduction requires cross-linking of several surface Ig 
receptors, which occurs during binding of an aggregate of antigenic molecules, or 
with repeating epitopes within the same molecule, which is commonly observed in 
larger molecules such as polysaccharides and lipids. Non-covalent association of 
the BCR with the Igα and Igβ chains mediates intracellular signal transduction 
through the BCR complex, with a series of phosphorylation steps similar to that of 
TCR signalling. Importantly, B cells are able to recognise unprocessed antigens, 
resulting in subsequent production of antibodies with the same specificity as the 
reactive surface BCR. The early phase of the humoral immune response therefore 
generally involves secretion of soluble IgM, the antigen receptor of naïve B cells. 
 
1.9.2 T-B cell interaction 
As most protein antigens do not contain repetitive epitopes, their ability to 
independently stimulate B cells is limited, and generation of efficient antibody 
responses therefore requires interaction of T and B cells specific for the same 
antigen. Fortunately, B cells are highly potent professional APCs for antigens they 
specifically recognise. Hence, BCR recognition of a protein antigen leads to its 
internalisation and degradation, followed by presentation of T cell-specific 
epitopes on HLA class II molecules (Fig. 5). 
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Upon activation, B cells downregulate expression of chemokine receptor CXCR5, 
which serves to retain naïve cells in the follicles, and instead upregulate CCR7, 
enabling migration towards the border of the T and B cell zones. Conversely, CD4+ 
T cells activated by the same antigen reduce their expression of CCR7 and instead 
express CXCR5, thereby causing movement towards the B cell zone. Initial T-B cell 
contact occurs in the extrafollicular space, where B cells present the processed 
antigen to T cells, ensuring antigen reactivity of T and B cells remains the same 
although the TCR and BCR recognise different epitopes. In return, B cells receive 
“T cell help” through the interaction of CD40L on the activated T cell and CD40 on 
the B cell. Engagement of the CD40 receptor promotes clonal expansion of B cells 
and differentiation into antibody-producing plasma cells. Extrafollicular plasma 
cells are usually short-lived, and produce antibodies of relatively low affinity. 
Following interaction with B cells, CXCR5high TH cells can migrate into the follicles 
and differentiate into follicular T helper (TFH) cells. TFH cells may originate from 
either naïve T cells or previously differentiated cells of any TH subset, in which 
case they will continue to produce subset-specific cytokines. In general, TFH cells 
are commonly distinguished by their expression of PD-1 and inducible co-
stimulator (ICOS), in addition to CXCR5 and CD40L, as well as transcription factor 
Bcl-6 and production of high levels of IL-21 (1). 
 
 
Figure 5 | T-B cell interaction. Graphic representation of the initial stages of T-B cell interaction 
in secondary lymphoid organs, depicting the opposing switch in chemokine receptor expression 
allowing for synchronised migration to the follicular border, subsequent interaction of T and B cells 
activated by the same antigen, and differentiation of B cells into antibody-producing plasma cells. 
Continuous antigen presentation by FDCs and survival signals provided by TFH cells are central to 
the GC reaction and generation of class-switched, high-affinity B cells. 
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1.9.3 Class-switch recombination and affinity maturation 
Activated B cells also migrate back into the follicle, where their continued 
interaction with TFH cells initiates isotype switching and affinity maturation in a 
specialised structure termed the germinal centre (GC) (Fig. 5). A combination of 
CD40L-mediated signals and cytokines released from TFH cells stimulates B cell 
expression of the enzyme activation-induced deaminase (AID), which drives 
rearrangement of the Ig heavy chain gene. Splicing of the previously recombined 
VDJ exon onto different constant region exons generates antibodies of different 
subclasses, but with the same epitope specificity, thus facilitating specialised 
effector functions that are ideally suited to the nature of the antigen. Moreover, 
extensive somatic hypermutation orchestrated by AID introduces point mutations 
in the V region, and particularly the hypervariable CDR3 segment primarily 
involved in antigen binding, in order to increase antibody affinity. Continuous 
antigen presentation by specialised follicular dendritic cells (FDCs) in the GC 
enables antigen-driven selection of B cells with the highest-affinity BCR. These 
cells are provided survival signals and TFH help, promoting further mutagenesis 
and production of new antibodies. GC B cells may enter the circulation as mature, 
long-lived plasma cells, which continue to produce high-affinity antibodies long 
after antigen clearance and provide immediate protection upon re-exposure. 
Other isotype-switched, affinity-mature B cells persist in the form of memory 
cells, which reside in tissues and monitor the circulation, responding rapidly to 
reintroduction of the antigen with clonal expansion and production of already 
class-switched high-affinity antibodies (1). Although the mechanisms that govern 
differentiation into either plasma or memory cells are not fully understood, the 
duration of T-B cell interaction (46, 47), the time point of the GC reaction when 
cells are generated (48), regulation of transcription factor Bcl-6 by CD40 and IL-21 
signalling (49, 50) and affinity for the antigen (51) have all been proposed to 
influence B cell fate. 
 
1.10 LYMPHOCYTE SELECTION, TOLERANCE AND AUTOIMMUNITY 
During maturation, both T and B cells undergo a sequential selection process, the 
purpose of which is to ensure functionality of the antigen receptors as well as 
deletion of potentially harmful, self-reactive cells. Initial selection is provided 
during TCR and BCR generation; failure to generate a functional receptor results 
in apoptosis. Once the whole receptor has been assembled on the cell surface, its 
ability to recognise ubiquitous self-antigens, such as abundant blood proteins or 
membrane molecules, will determine cell fate. A high-affinity binding to the HLA-
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antigen complex results in death by negative selection, as these cells may be 
activated without the need for second signals, and could propagate destructive 
autoreactive responses. Conversely, lack of recognition, which would render the 
cell incapable of mounting a response to harmful agents, leads to death by neglect, 
as the cell does not receive the appropriate survival signals from the APC. Positive 
selection occurs when the antigen is recognised with low affinity, the intracellular 
signalling cascade being triggered by the aid of co-receptors and co-stimulatory 
molecules on the APC. Specifically, immature T cells express both co-receptors 
CD4 and CD8, and recognition of an antigenic peptide in complex with either HLA 
class I or class II results in downregulation of the unbound co-receptor and 
thereby commitment to either the CD4+ TH or the CD8+ CTL lineage (1). 
 
Immunological tolerance refers to the lack of response elicited by lymphocytes 
exposed to certain antigens, most commonly harmless foreign agents and self-
antigens. Central tolerance is mediated through negative selection in the 
lymphoid organs, as well as generation of TREGs that act to restrict self-reactive 
lymphocyte responses in the periphery through secretion of immune-dampening 
cytokines and expression of co-inhibitory receptors. Peripheral tolerance also 
comprises induction of anergy, which occurs when an antigen is recognised 
without proper co-stimulatory signals and the lymphocytes are rendered 
functionally inactive. Autoreactive cells can also be deleted by triggering of 
apoptosis, either through release of pro-apoptotic signals or expression of the 
death receptor-ligand pair Fas-FasL in response to recognition of self-antigens (1). 
Importantly, however, estimates have shown approximately 20% of circulating B 
cells to be autoreactive without causing disease (52). Conversely, as tissue-specific 
or intracellular antigens are normally not presented in secondary lymphoid 
organs, lymphocytes recognising these antigens may not be deleted by negative 
selection and are thus able to undergo clonal expansion unhindered when 
confronted with release of intracellular components during necrosis, or tissue-
specific factors secreted during trauma. 
 
Failure of tolerance mechanisms, which commonly occurs due to a combination of 
genetic and environmental factors, can result in autoimmunity. HLA genes are the 
most commonly associated with heritable predisposition, and different HLA alleles 
and haplotypes have been shown to influence susceptibility for or protection 
against the development of certain immune-mediated and autoimmune diseases. 
For example, HLA-DRB1*15 (DR15 haplotype) is tightly linked to a predisposition 
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to develop MS (53, 54), and HLA-DRB1*04 (DR4) to RA (55). HLA-DQB1*02 (DQ2.5) 
confers increased risk of coeliac disease, while its homologue DQ2.2 reduces the 
risk of the same condition (56). In addition, polymorphisms in genes associated 
with lymphocyte regulation or activation, such as CTLA-4, CD25 (the IL-2 receptor α chain), the IL-23 receptor (IL-23R) and protein tyrosine phosphatase N22 
(PTPN22) have also been implicated in several multifactorial autoimmune diseases 
(1). Furthermore, autoreactive lymphocytes can be activated during an infection, if 
the presented epitopes closely resemble the specificity of the TCR or BCR. Other 
potential risk factors for development of autoimmunity include exposure to 
environmental agents (57), gender (58), and smoking (59). 
 
1.11 THE RESPIRATORY SYSTEM 
1.11.1 Anatomy of the airways 
The lungs are located in the thoracic cavity, protected by the rib cage and 
separated from the gastrointestinal system by the diaphragm, which is controlled 
by the sympathetic nervous system and the main muscle involved in breathing. 
The left lung, which shares space with the heart, is slightly smaller and consists of 
two lobes, while the right lung comprises three. Each lung is enclosed within a 
pleural sac, containing a serous fluid that minimises friction during breathing. The 
respiratory tract can be divided into the upper, comprising the nasal cavity, 
pharynx and larynx, and lower compartment, including the trachea, bronchial tree 
and alveoli. Following entry through the nose and mouth, air travels through the 
trachea to the bifurcation between the right and left primary bronchi. These larger 
airways divide into secondary (lobar) and tertiary (segmental) bronchi, gradually 
branching into smaller bronchioles. Eventually, the terminal bronchioles cross 
over into the alveolar ducts, marking the transition from the conducting zone to 
the respiratory zone and connecting to the specialised structures of the alveolar 
sacs where gas exchange occurs. Between 300 and 500 million alveoli, each 
surrounded by a fine lattice of pulmonary capillaries facilitating transfer of oxygen 
to the blood and carbon dioxide back to the lungs for discharge, together provide a 
total pulmonary surface area of approximately 120 m2 (60). 
 
1.11.2 Pulmonary immunology 
The airway epithelium is the first line of defence against harmful airborne agents, 
including microbial pathogens, toxins and pollutants. Continuous epithelia along 
the interface to the external environment provide steric hindrance for entry of 
microorganisms, as well chemical interference through production of anti-
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bacterial defensins and cathelicidins. In addition to its physical barrier, ciliated 
cells and mucous-producing goblet cells along the epithelial lining enable efficient 
clearance of foreign particles. Airway epithelial cells also act as important triggers 
of innate and adaptive immune mechanisms in the lung through production of 
antimicrobial substances as well as pro-inflammatory cytokines and chemokines 
(61, 62). Early immune responses are also mediated by intraepithelial T 
lymphocytes, which express γδ TCRs of limited diversity. In contrast to traditional αβ T cells, γδ T cells do not require antigen processing and presentation by APCs 
and are able to recognise microbial lipids as well as general danger signals, e.g. 
heat-shock proteins. However, a certain degree of receptor rearrangement has 
been observed, as well as development of a memory phenotype, presumably in 
response to frequently encountered microbial threats (1). 
 
Alveolar macrophages are resident phagocytic cells constituting 90-95% of all 
respiratory leukocytes in a healthy individual; in contrast, lymphocytes account 
for 1-10% and neutrophils roughly 1% (63). Apart from phagocytosis of harmful 
particles, macrophages are responsible for release of reactive oxygen species 
(ROS), nitric oxide (NO) and proteolytic enzymes that can directly kill invading 
pathogens (64), as well as antigen presentation to T cells. In addition, DCs residing 
beneath the airway epithelium migrate from the mucosa to the thoracic lymph 
nodes to present antigen and prime T cell responses (65). Unique to mucosal 
organs are discrete collections of lymphocytes and APCs with a similar 
organisation to that observed in lymph nodes. At any given time, at least a quarter 
of the body’s lymphocytes reside in the mucosal tissues and skin, most of which 
are memory cells. Mucosal tissues also comprise a specific subset of B cells, termed 
B-1 cells, which are self-renewing and able to secrete natural antibodies, i.e. 
antibodies produced even in absence of encountered pathogens, in response to 
non-protein antigens without requirement for T cell help, as well as to generate 
memory responses (66). The primary antibody type produced in mucosal lymphoid 
organs is IgA, which can be transported across the epithelium, bind to and 
neutralise microbes present in the lumen of the respiratory tract. Cytokines 
inducing class-switching of B cells to IgA, most prominently TGF-β, are constantly 
produced at high levels in mucosa-associated lymphoid organs, and IgA-producing 
B cells are predisposed to recirculate to mucosal tissues and home to specific sub-
epithelial sites (1). 
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Insufficient or exaggerated immune responses in the lung can lead to pathological 
conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and 
interstitial lung diseases (ILDs), which include, among others, idiopathic 
pulmonary fibrosis (IPF), non-specific interstitial pneumonia, chronic beryllium 
disease (CBD), silicosis and sarcoidosis. Though the triggering factor may vary, 
ILDs (also termed diffuse parenchymal lung diseases) share distinct clinical 
features of diffuse lung infiltrates on chest radiography and distortion of gas 
exchange, resulting in restriction of respiratory volume and impaired oxygenation 
(67, 68). 
 
1.12 SARCOIDOSIS 
1.12.1 Clinical characteristics 
Sarcoidosis is a granulomatous multisystem disorder of unknown aetiology. The 
disease primarily manifests in the lungs, which are affected in approximately 90% 
of cases, but can also target other organs such as the eyes, spleen, skin, liver, 
kidney, heart and central nervous system (CNS) (69, 70). It mainly affects young 
adults between 30-50 years of age, but may arise in adults of all ages; especially for 
women, a second peak of incidence can be observed around 60 years of age (71). 
Globally, the disease is most prevalent in Northern European countries, where 
disease is usually resolving, and in African-Americans, who generally experience a 
more severe disease and are prone to develop chronicity (72). The incidence in 
Sweden is approximately 1200 new cases yearly, and more than half of all patients 
develop a disease with more than two years’ duration. While the main clinical 
symptoms are a non-productive cough and dyspnoea, fatigue and arthralgia are 
common features with major influence on the patient’s quality of everyday life (73, 
74). For patients with chronic disease, pulmonary fibrosis, cardiac and CNS 
involvement are the major causes of sarcoidosis-associated mortality (69). 
 
1.12.2 Immunopathogenesis and diagnosis 
Histologically, the characteristic finding in sarcoidosis is the presence of non-
caseating granulomas in the affected organs (Fig. 6). These aggregates of highly 
differentiated immune cells develop upon accumulation of alveolar macrophages 
and DCs at sites of inflammation and an ensuing inability to completely eliminate 
the antigenic source, which resists degradation either due to size, insolubility or 
inherent anti-phagocytic properties. Instead, under the influence of abundant 
inflammatory signals, activated macrophages and DCs fuse to form multinucleated 
giant cells (MGCs) (75), which are surrounded by activated T cells to which antigen 
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is presented (76). Encapsulation of the antigen by deregulated immune cells 
prevents its dissemination, while the failure of antigen clearance results in 
persistence of granulomas, in severe cases leading to necrosis and fibrotic scarring 
of associated tissue. The sarcoid granuloma consists of two segments: the core 
region, comprising tight clusters of macrophages, epithelioid cells and a few 
MGCs, and the surrounding crust, containing high numbers of T cells and few B 
cells (77). Although not typically observed within sarcoid granulomas, higher 
numbers of neutrophils have been detected in patient lungs compared to healthy 
controls (78), and especially in patients with more severe disease (79). Moreover, 
impaired oxidative phosphorylation of mitochondrial proteins is believed to 
contribute to ROS production, inflammatory signalling and tissue damage in 
chronic sarcoidosis (80). DCs from sarcoidosis patients also produce higher levels 
of TNF-α compared to healthy individuals, suggesting a feed-forward loop driving 
DC maturation, migration and granuloma formation (81).  
 
Figure 6 | Structure of the sarcoid granuloma. Histological image of a classically well-structured 
non-caseating granuloma, accompanied by a graphic representation of its components. Most 
prominently, the sarcoid granuloma comprises a core of macrophages and DCs, occasionally fused 
to MGCs, surrounded by an outer crust of lymphocytes, the majority of which are CD4+ T cells, 
interspersed with CD8+ T cells and a few B cells. 
Lymphocyte involvement is dominated by T cells and particularly CD4+ TH cells, 
which are essential contributors to granuloma formation, maintenance and overall 
disease outcome. IL-12 and IL-18 secreted by macrophages and DCs at the 
inflammatory site drive differentiation of T cells, which in turn secrete high levels 
of IFNγ and IL-2, propagating both macrophage activation and T cell survival (76). 
Release of ligands for chemokine receptor CXCR3, most notably CXCL10, by 
macrophages further ensures migration of T cells to the granulomatous region 
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(82). In addition, IL-17A-producing memory T cells are found within and in the 
vicinity of sarcoid granulomas (83, 84), and both IFNγ and IL-17A are believed to 
be central to the process of granuloma formation (85-87). 
 
On a cellular level, one of the hallmark signs of sarcoidosis and a major diagnostic 
criterion is a pronounced lymphocytosis (>25%) and an elevated CD4/CD8 T cell 
ratio (>3.5) in bronchoalveolar lavage fluid (BALF) (88), and repeated studies have 
firmly established sarcoidosis as a primarily CD4+ T cell-driven disease (69, 89). 
Additional diagnostic parameters include characteristic findings on chest 
radiography (Table 1) and lung function tests, as well as measurement of blood 
biomarkers, most prominently elevated levels of serum angiotensin-converting 
enzyme (ACE) and free calcium, which associate with macrophage activation and 
have been postulated to reflect an increase in granulomatous activity (90). A 
negative tuberculin (PPD) test, as well as exclusion of differential reasons for 
granuloma formation, such as malignancy, infectious disease or systemic 
autoimmunity, are also required for establishing the diagnosis. 
 
Table 1 | Clinical staging in sarcoidosis according to findings on chest radiography. 
 
1.12.3 Clinical and molecular basis of disease phenotypes 
Sarcoidosis appears in two forms, which are mainly distinguished based on clinical 
criteria; the underlying immunological mechanism(s) largely remain unknown. 
Löfgren’s syndrome (LS), first described in 1946 by Swedish pulmonologist Sven 
Löfgren (91), presents with an acute onset, usually fever, active inflammation and 
characteristic clinical symptoms such as bilateral hilar lymphadenopathy (BHL) 
(Fig. 7), erythema nodosum and/or ankle arthritis. Women more frequently 
present with erythema nodosum, while men commonly develop bilateral ankle 
arthritis (92). In Sweden, approximately one third of all sarcoidosis patients are 
diagnosed with LS (93, 94). “Non-LS” patients show a slower onset and are more 
heterogeneous in disease presentation, but commonly suffer from fatigue, low-
Chest radiographic stage Characteristic findings 
0 Normal findings 
I BHL without pulmonary infiltrates 
II BHL with pulmonary infiltrates 
III Only pulmonary infiltrates without BHL 
IV Signs of fibrosis and volume reduction 
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grade fever and weight loss. While LS patients usually experience a more rapid and 
spontaneous disease resolution and have a good prognosis, non-LS patients are at 
a higher risk of developing chronic disease, of which 20-25% eventually progress 
to pulmonary fibrosis. Mortality rates range between 1-5%, usually due to severe 
fibrosis and/or myocardial or CNS engagement (69). Due to its distinct clinical 
characteristics, LS has even been suggested to be considered as a separate disease 
(93). Recent genetic studies have revealed distinct differences between LS and 
non-LS, with LS patients being genetically more homogenous, and exhibiting gene 
associations not present in non-LS, and vice versa (95). LS is closely linked to 
presence of specific HLA allele DRB1*03, which appears to be a strong prognostic 
factor in sarcoidosis. Of HLA-DRB1*03+ LS patients, 95% resolve spontaneously 
within two years; for HLA-DRB1*03- LS patients, this number plunges to 50% (93). 
Other HLA-DR alleles have also been demonstrated to influence disease outcome; 
most notably, HLA-DRB1*14 and HLA-DRB1*15 appear to associate with 
chronicity (96-98), while HLA-DRB1*04 is overrepresented among patients with 
ocular involvement (99). In addition to HLA genes, various polymorphisms in the 
butyrophilin-like 2 (BTNL2) gene have been shown to influence development of LS 
and non-LS, respectively (100). BTNL-2 is a co-inhibitory receptor distinct from 
the CD28-CTLA-4 axis, acting to negatively regulate T cell activation by 
promoting de novo FoxP3 expression (101). Moreover, polymorphisms in 
chemokine receptor genes CCR2 and CCR5 have, independently of HLA-DRB1*03 
(102, 103), been associated especially with LS, and in the case of CCR5, specifically 
in females (104). Other prominent genetic variants linked to development of either 
LS or non-LS disease include the major histocompatibility complex 2 
transactivators (MHC2TA) (105), macrophage migration inhibitory factor (MIF) 
(106) and isoforms of TGF-β (107). 
 
 
Figure 7 | Bilateral hilar lymphadenopathy on chest radiograph. A representative image of the 
bilateral enlargement of hilar lymph nodes commonly observed in sarcoidosis, and most notably in 
LS, as visualised by standard chest radiography. 
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1.12.4 Disease aetiology 
The causative agent(s) in sarcoidosis have yet to be identified. Over the years, 
postulated causes have included infectious agents (108), e.g. Mycobacterium 
tuberculosis (109, 110) or Propionibacterium acnes (111-113), exposure to 
environmental irritants such as dust particles from construction sites (114), 
protein misfolding (115), or, most recently, autoimmunity (116, 117). 
 
Sarcoidosis has been shown to be transmissible to naïve transplant recipients from 
donors not known or suspected to have active disease (118), reminiscent of 
involvement of an infectious agent. The strive for HLA compatibility during 
transplantation should, however, be accounted for, as an environmental or self-
antigen readily available in the inflammatory environment of the donor could 
theoretically be recognised also by a recipient with a shared HLA background. 
 
The similarity of sarcoidosis pathology to that of tuberculosis, most prominently 
characterised by granuloma formation in the lungs, initially suggested a common 
origin. Myco- and propionibacterial DNA and protein have been identified in 
sarcoid granulomas, and several studies show reactivity of lung-derived T cells to 
mycobacterial proteins (109), most frequently mycobacterial catalase-peroxidase 
(mKatG), the 6 kDa early secretory antigenic target (ESAT-6) and heat-shock 
proteins (119, 120). Opinions differ on the exact disease mechanism, but it has 
been suggested that sarcoidosis is caused by immune reactivity towards 
incompletely degraded bacterial antigens (121). However, as presence of bacterial 
DNA (122) and protein (110) has been reported in approximately 50% of 
investigated sarcoidosis patients, and as live mycobacteria have never been 
identified in sarcoid lungs, these findings cannot account for all patients. 
Moreover, mechanistic studies of M. tuberculosis infection show that the 
granulomatous environment itself attracts infected cells that may contribute to 
augmented pathogenesis and prolonged immune responses, which could account 
for the presence of bacterial remnants without clinical signs of a previous 
infection. 
 
While a seasonal variation in disease onset (123), particularly for LS, points to 
involvement of an infectious agent, another explanation could be the influence of 
an environmentally-derived triggering factor, the accessibility of which fluctuates 
with the seasons. Fittingly, sarcoidosis has been associated with exposure to 
environmental irritants such as tree pollen, inorganic particles and mouldy 
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environments (124, 125). Moreover, an increased incidence of sarcoidosis-like 
disease has been observed in construction workers (126), military personnel and 
firemen (69), most recently in the aftermath of the World Trade Center 
catastrophe in 2001 (114, 127-129). However, such exposure also appears to 
associate with other, unrelated lung diseases (130). 
 
Serum amyloid A (SAA) proteins are secreted from the liver during the acute phase 
of inflammation, serving to recruit immune cells to the site of injury and mediate 
induction of enzymes that degrade the extracellular matrix. Macrophages are a 
major source of SAAs in inflammatory conditions, and elevated levels of SAA have 
been reported in RA, diabetes type II and Crohn’s disease (131), as well as in 
sarcoidosis (132, 133). Interestingly, expression of SAA in sarcoid granulomas 
appears to be distinct from that of other granulomatous disorders, including CBD, 
Crohn’s disease, Wegener’s granulomatosis, and tuberculosis. It has been 
hypothesised that SAA is generated as part of the acute phase reaction following 
an infection, and that misfolded and/or aggregated protein products propagate 
further release and accumulation of SAA in the granuloma. Inability to clear SAA 
and trapped antigens, partly dependent on genetic and/or epigenetic factors, 
would thereby lead to chronic inflammation and fibrosis (119, 134). However, SAA 
induction is a rapid, unspecific response, with elevated levels being detected 
within hours of exposure to often relatively trivial inflammatory stimuli, and 
might therefore be a general sign of an ongoing inflammatory reaction rather than 
a disease-specific trigger in itself. Nonetheless, its value as a prognostic marker for 
chronic disease as opposed to remission ought to be further explored. 
 
The concept of sarcoidosis as an autoimmune disease is supported by the strong 
HLA connection in LS patients, and the higher prevalence of disease in first-
degree relatives (135). Moreover, a markedly higher risk of developing disease has 
been documented in monozygotic compared to dizygotic twins (136), suggestive of 
an imperative hereditary component. In addition, these patients are generally 
young, previously healthy, and non-smokers (94). If this is the case, however, 
sarcoidosis would be one of very few self-limiting autoimmune conditions, as the 
disease, especially in LS patients, usually resolves spontaneously. Nevertheless, it 
has been shown that in a small group of patients (<5%), the disease can relapse 
later in life (137, 138), though whether this is to be regarded as re-infection or an 
autoimmune flare remains unknown. Notably, in HIV+ patients receiving highly 
active anti-retroviral therapy (HAART), sarcoidosis has been observed to appear 
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with regained CD4+ T cell counts >200 cells/mm3 (139, 140), which is the opposite 
scenario from what would be expected in an infectious disease. Furthermore, 
sarcoidosis-like disease has been reported in patients administered IFN	treatment 
for malignancy, hepatitis C infection or immune-mediated disorders (141-143). 
Patients treated with anti-CTLA-4 or anti-PD-1 (e.g. due to metastatic melanoma) 
are also at higher risk of developing sarcoidosis (144-150), possibly due to 
impaired TREG-mediated responses, again implicating immune hyperactivity rather 
than deficiency in disease pathogenesis. 
 
In 1941, Norwegian pathologist Morten Ansgar Kveim first reported the diagnostic 
use of a skin test based on intradermal injection of a pasteurised saline suspension 
of sarcoid lymph node tissue (151). Over the following weeks, patients with active 
sarcoidosis, but not healthy controls, would develop granulomatous structures in 
the skin at the site of injection, which would be verified as sarcoid tissue upon 
histological examination (152, 153). The method was commercialised by American 
physician Louis Siltzbach in 1954, then using spleen tissue. Despite being 
discontinued in 1996 due to risk of transferred infections, the use of such a 
mixture of undefined, granuloma-derived proteins for diagnostic purposes 
suggests reactivity to one or several of the contents of the Kveim reagent to be 
central to the disease process (154-156). One such recently identified component 
is vimentin, a type III intermediate filament protein expressed in mesenchymal 
cells and an important constituent of the cellular cytoskeleton (157). Previous 
studies utilising mass spectrometry have, on separate occasions, identified a 
vimentin-derived peptide as bound to HLA-DR on alveolar macrophages in BALF 
of HLA-DRB1*03+ sarcoidosis patients (116, 117, 158). Intriguingly, the HLA-
DRB1*03 allele has also been shown to influence the outcome of autoimmune 
disease systemic lupus erythematosus (SLE) (159), as well as thus far unresolved 
conditions such as Langerhans cell histiocytosis (160) and idiopathic inflammatory 
myopathies (161, 162). In SLE, elevated levels of anti-vimentin antibodies have 
been found in patients with the severe kidney manifestation tubulointerstitial 
nephritis (163), implicating vimentin in the pathogenesis of several autoimmune 
disorders. Following citrullination, a process commonly induced by smoking, 
vimentin also acts as a target in RA (164, 165). Antibodies against citrullinated 
vimentin can be found in the lungs prior to clinical onset of disease (166), 
suggesting that disease-initiating events in autoimmune conditions may occur in 
the lungs regardless of the target organ from which clinical symptoms are 
observed. In contrast to RA, smoking is not considered a risk factor for sarcoidosis 
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and even shows a negative correlation with disease development (124), which 
could possibly be explained by differences in vimentin reactivity: in one case the 
modified form of the protein is recognised, in the other, the native form. 
 
It is also possible that the true cause of the disease stems from a combination of 
the above-mentioned factors, as in the case of transient autoimmunity (167, 168). 
Alternatively, dual reactivity to several antigens of different origin can arise due to 
molecular mimicry. TCR recognition of a microbial antigen followed by cross-
reactivity of activated T cells to a structurally similar self-peptide can result in 
autoimmune responses, which abate as the pathogen is cleared (169). A third 
possibility is that of an autoimmune reaction following allergic hypersensitivity 
(170), for example to certain metals (171) or inorganic compounds. Exposure to 
silica, which is abundant in nature, as well as an integral component of several 
industrial products such as glass, ceramics and cement (172), has been associated 
with silicosis (173), which is usually a progressive, fibrotic condition, but also with 
RA, SLE and sarcoidosis (174). Modified silica particles, e.g. in crystalline format 
(175), could promote macrophage activation, antigen presentation and subsequent 
responsiveness not only to silica but also to cellular components released by 
damaged macrophages. Intriguingly, recent years have seen the successful 
exploration of CBD, another granulomatous lung disorder with a strong HLA 
association (in this case to HLA-DP2) and notable similarities to sarcoidosis in 
terms of disease presentation and histological picture. It was found that all 
affected patients had been previously exposed to beryllium, allowing Be2+ ions to 
interfere with TCR recognition of HLA complexes presenting self-peptides in the 
lung. Upon Be2+ binding, T cell epitopes would be altered, subsequently causing 
recognition of a self-peptide (in this case plexins derived from the pulmonary 
epithelium) and initiation of immune responses (170, 176, 177). In contrast to 
sarcoidosis, however, CBD patients generally experience a chronic disease, as 
beryllium is not readily degraded or eradicated once it has entered the lung. The 
association of the Be2+ ion with the peptide-binding cleft of the HLA molecule also 
stabilises the TCR-HLA complex, ensuring continuous antigen presentation and 
presence of a stable, autoreactive CD4+ T cell pool in the lung (170, 178, 179). 
 
Similar to CBD, where populations of clonal CD4+ T cells are observed in BALF, 
CD4+ T cells expressing the TCR α chain variable segment Vα2.3 have previously 
been found to accumulate in the lungs of HLA-DRB1*03+ sarcoidosis patients. 
These expansions of TCR-specific cells are found exclusively in BALF of HLA-
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DRB1*03+ patients with active disease, and not in HLA-DRB1*03+ healthy 
individuals or patients with other pulmonary disorders (180). Neither are they 
present in regional lymph nodes, nor peripheral blood (181), and Vα2.3+ T cell 
counts decrease upon clinical resolution (182). Moreover, in contrast to CBD, the 
higher the level of Vα2.3 cells at the time of lavage, the more rapid the resolution 
and better the prognosis (183). More recently, an accumulation of CD4+ T cells 
expressing the Vβ22 TCR chain segment was also identified in BALF of HLA-
DRB1*03+ patients (184), which prompted further investigation of HLA-DRB1*03, 
the Vα2.3 and Vβ22 TCR segments in combination, and the proposed influence of 
vimentin peptides on sarcoid inflammation, the results of which are presented in 
this thesis. 
 
1.12.5 CD4+ T cell subsets in sarcoidosis  
Overall, T cell proliferation and cytokine production is much more pronounced in 
the lungs than in peripheral blood, suggesting the immune reaction to be, 
although potentially systemic, primarily targeting an inhaled or lung-inherent 
antigen (181, 185). In the lungs, the vast majority of CD4+ T cells are defined as 
effector memory T cells, characterised among others by expression of CD45RO, 
loss of CD27 (which occurs during prolonged antigen stimulation and T cell 
differentiation) (186) and elevated expression of CD69 (a marker of tissue-resident 
memory cells). Notably, CD69+ T cells have also been postulated to be involved in 
autoimmune lung diseases (187). 
 
Sarcoidosis has traditionally been considered a TH1-driven disease, due to the high 
levels of IFNγ, IL-2 and TNF-α produced by BALF T cells and alveolar macrophages 
(134, 188), presence of TH1-skewing cytokines IL-12 and IL-18 (185, 189, 190), as 
well as the high T cell expression of chemokine receptors CXCR3 and CCR5 (191). 
In contrast, TH2-associated patterns of IL-4 and IL-5 production and surface 
expression of CCR4 are reduced in sarcoid lungs (188). However, several studies 
have reported involvement of IL-17 in the disease process (83, 84, 192, 193). IL-17 
responses and genes involved in the TH17 and TH22 pathways also appear to act 
primarily in LS, further highlighting the importance of distinguishing between the 
two disease forms, both at a clinical and a molecular level (95). The role of TH17 
and so-called TH1/TH17 “hybrid” cells in autoimmune conditions such as RA, SLE, 
MS and psoriasis (13-17), where they are believed to be of pathogenic nature, in 
contrast to their potentially protective properties in mucosal organs, is a matter 
under current investigation. In sarcoidosis, IFNγ+IL-17A+ double-producing cells 
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have been implicated as the main drivers of inflammation, especially if 
transitioning to an IFNγ-single-producing phenotype (193), and are further 
recognised as mediators of glucocorticoid-refractory disease (194). However, lack 
of a clear consensus on how to characterise these cells in the lung complicates 
understanding of their functionality. It also remains to be determined whether the 
granulomatous environment in itself may promote T cell plasticity (195). 
Interestingly, IFNγ has also been shown to stimulate production of B cell-
activating factor (BAFF) by monocytes (196). Elevated serum levels of BAFF have 
been reported in sarcoidosis patients (196, 197), and have been shown to affect 
TH17 differentiation in vitro (198), suggesting potential B cell involvement in 
influencing T cell differentiation under inflammatory conditions. 
 
TREGs in sarcoidosis have also been the subject of contradictory reports, with either 
a reduction of FoxP3+ CD4+ T cells (199, 200) or an increase in numbers, but with 
defective functional capacity, being observed. The latter has interchangeably been 
measured in terms of e.g. IL-10 production (201), expression of CTLA-4 (145), 
survival (202) or potency in suppression of effector cell proliferation and cytokine 
secretion (202-205). As with effector cells, the interpretation of these results is 
complicated by the fact that different studies use different markers to define a 
particular cell subset. Especially in a tissue compartment such as the lung, the 
phenotype of several cells may differ significantly from that of the same subset in 
blood. It is also plausible that both regulatory and effector cells in tissues express 
specific markers that optimise activity within a certain microenvironment, 
potentially leading to their misclassification. Regardless of cell phenotype, 
increased levels of IL-10 have been observed in sarcoidosis, and especially in LS 
patients (201), suggesting at least parts of the disease process to involve features 
of immune regulation. As previously stated, inhibitory receptors CTLA-4, PD-1 
and BTNL-2 are essential to TREG function and their dysregulation in sarcoidosis 
has repeatedly been suggested to contribute to disease pathogenesis (195). The 
closely linked developmental programmes of TH17 cells and TREGs also implicate a 
switch from anti-inflammatory TREGs to pro-inflammatory TH17 cells under 
conditions of receptor blockade (150), which impairs TREG-mediated suppression. 
In patients with CBD, antigen persistence has been observed to reduce the 
requirement for CD28 signalling in response to TCR engagement, eventually 
resulting in dysfunctional CTLA-4 and PD-1 pathways (206, 207), which could 
potentially parallel the situation in chronic sarcoidosis. 
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1.12.6 Current and future treatment opportunities 
There is currently no efficient treatment for sarcoidosis, and a majority of 
patients, especially with LS, remain untreated, though oral corticosteroids alone 
and/or in combination with methotrexate (208) or azathioprine (209) are generally 
prescribed in patients with severe pulmonary dysfunction and persistent infiltrates 
(88, 210). In general, the current therapeutic strategy is to reduce the immediate 
and potential long-term negative impact of disease on everyday quality of life, as 
well as to improve the most persistent and disabling symptoms, particularly 
fatigue, pain, cognitive impairment, depression and small fibre neuropathies (70). 
Corticosteroids constitute the first-line treatment and are usually the most 
effective in terms of rapid symptomatic amelioration (211). However, long-term 
treatment is contraindicated due to the sometimes severe side effects, including 
among others weight gain, diabetes, hypertension, muscular atrophy, 
osteoporosis, depression and infections (212, 213). Low-dose immunosuppressive 
and/or -modulatory drugs, most prominently methotrexate or azathioprine, are 
recommended as second-line treatment in steroid-refractory disease, or as a 
“steroid-sparing” agent when prolonged high-dosage treatment is predicted to be 
required (214, 215). Up to 60-80% of cases of steroid-resistant sarcoidosis have 
been found to respond to methotrexate (216), which has proven particularly 
efficient for management of ocular and neurological manifestations (217, 218). 
Azathioprine has been similarly beneficial in facilitating corticosteroid reduction, 
as well as improving lung function parameters (209). In addition, cyclosporine has 
been tried as a means of restricting T cell activity and cytokine production (219). 
As a third-line treatment, TNF-α inhibitors, most commonly infliximab, are used 
for refractory sarcoidosis not responding to conventional immunosuppressive 
drugs, due to their role in prevention of initiation and propagation of granuloma 
formation (220). The efficacy of these treatment strategies is, however, highly 
patient-specific, and there is an evident call for superior therapeutic options (210, 
221). Essentially, more individualised and targeted treatment is required to 
achieve complete disease resolution (if possible). Current research therefore 
strives to identify the disease-initiating antigen(s) in order to apply this 
knowledge with the aim of improving diagnostic, prognostic, therapeutic and 
potentially preventive measures. 
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2 AIMS 
The two parallel, but intertwining, aims of this thesis was to conduct a detailed 
investigation of CD4+ T cell-mediated pulmonary inflammation in clinically 
distinct phenotypes of sarcoidosis, and, with the aid of known TCR specificity, to 
identify disease-specific antigens driving such inflammation. 
 
For the separate studies, specific aims were: 
 
Paper I 
To investigate expression of the newly identified TCR V segment Vβ22 in 
conjunction with Vα2.3 on lung CD4+ T cells, and to evaluate the differentiation 
status and clonality of these cells as an indication of their possible role in antigen 
recognition. 
 
Paper II 
To identify factors related to TH1- and TH17-mediated inflammation, respectively, 
as well as T cell regulation, in LS and non-LS sarcoidosis, and the possible 
influence of T cell polarisation on clinical outcome. 
 
Paper III 
To expand on the findings in Paper II by conducting an unbiased study on CD4+  
T cells in the lungs of LS and non-LS patients, striving to identify novel 
immunological pathways that separate the two disease conditions. 
 
Paper IV 
To delve deeper into the results of Paper I by isolation and sequencing of the 
entire αβ TCR of sarcoidosis patients, specifically striving to elucidate consensus 
CDR3 motifs in HLA-DRB1*03+ patients to be used for future antigen discovery 
studies. 
 
Paper V 
To complement the T cell findings of Paper I with a B cell perspective, scrutinising 
antibody responses to vimentin in sarcoidosis patients and T-B cell interaction in 
the inflamed lung. 
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3 COMMENTS ON METHODOLOGY 
The experimental procedures underlying the work presented in this thesis are 
described in detail in the respective papers. This section serves as a general 
summary of the methodology used and its purposes, as well as limitations and 
pitfalls of the different techniques. 
 
3.1 STUDY SUBJECTS 
Patients with suspected sarcoidosis were committed to the Lung and Allergy Clinic 
at Karolinska University Hospital, Solna, Stockholm, Sweden, for primary 
diagnostic investigation in accordance with criteria established by the World 
Association of Sarcoidosis and Other Granulomatous Disorders (WASOG), 
American Thoracic Society (ATS) and European Respiratory Society (ERS) (88). 
Specifically, these included findings at bronchoscopy with bronchoalveolar lavage 
(BAL) including an elevated CD4/CD8 ratio, and if required, biopsies positive for 
granulomatous tissue, as well as exclusion of other diagnoses (primarily 
malignancy and infections). For all studies, patients with LS and non-LS 
sarcoidosis were considered separately. LS was defined as an acute onset, usually 
with fever, chest radiographic findings of BHL, with or without pulmonary 
infiltrates, and presence of erythema nodosum and/or bilateral ankle arthritis. 
Non-LS patients presented with varying symptomatic manifestations and severity, 
but commonly demonstrated an insidious onset, fatigue, dry cough and 
parenchymal changes. Unless otherwise specified, patients were untreated at the 
time of investigation. Healthy controls had normal chest radiography, no 
documented current infections and were not administered any medical treatment. 
All patients and healthy volunteers were HLA typed according to previously 
established protocols (222). Informed consent was obtained from all subjects, and 
ethical permission granted by the Stockholm County Regional Ethical Committee, 
with approval numbers 2005/1031-31/2, 2009/20-32, 2011/35-32 and 2012/132-32. 
Collaborative studies with the University of Colorado, Denver and University of 
Chicago were jointly approved by the respective local institutional review boards. 
 
3.2 CLINICAL SAMPLING 
3.2.1 Bronchoscopy with bronchoalveolar lavage  
Bronchoscopy is a clinical procedure that enables visual inspection of the 
conducting airways and sampling of cell and tissue material from the lungs (Fig. 
8). For sarcoidosis, histological assessment of cell composition and measurement 
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of CD4/CD8 ratio are routinely performed as part of the diagnostic procedure, for 
which reason patients are subjected to BAL as early as possible following 
admission to the clinic. Especially for LS patients, who experience a more acute 
but also self-limiting disease course, it is essential to perform bronchoscopy soon 
after disease onset, as the size and composition of the lymphocyte compartment 
change dramatically between active inflammation and remission, especially with 
regards to the percentage of TCR-specific Vα2.3+Vβ22+ T cells (182). For all 
studies, bronchoscopy and BAL were performed according to established 
procedures (223). Briefly, a flexible fibre-optic bronchoscope was introduced into 
the lower airways through the nose or mouth under local anaesthesia. Five 
aliquots of 50 ml sterile saline solution were instilled into the middle lobe of the 
right lung and recollected by aspiration. Cells in BALF were separated from 
recovered fluid by centrifugation, fixed on cytospin slides and stained with May-
Grünwald Giemsa for calculation of leukocyte differential count. Cell-depleted 
BALF was further centrifuged to ensure removal of cell debris and stored at -80°C 
until further use, among others the study of solutes such as proteins, peptides, 
lipids and antibodies. 
 
 
 
Figure 8 | Sampling of the lungs by bronchoscopy and bronchoalveolar lavage. 
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3.2.2 Measurements of lung function 
In all patients, lung function was assessed by spirometry using standardised 
parameters (224) (Fig. 9-10). Dynamic measurements included vital capacity (VC), 
forced vital capacity (FVC) and forced expiratory volume during one second (FEV1). 
In restrictive lung diseases such as sarcoidosis, a loss of pleural, parenchymal or 
extrapulmonary distensibility results in restricted capacity for expansion, whereby 
the total lung capacity (TLC) is reduced. This particularly prominent in patients 
with signs of pulmonary fibrosis, due to the gradual increase in scar tissue. In such 
instances, both FEV1 and FVC are reduced, resulting in an approximately normal 
(³80%), or even slightly elevated, FEV1/FVC ratio, as the decline in FVC is usually 
more drastic than in FEV1 (225) (Fig. 11). 
 
 
Figure 9 | Measurement of lung function by spirometry. 
 
In addition to spirometry, the diffusing capacity of carbon monoxide (DLCO), 
which reflects the extent to which oxygen passes from the alveoli into the 
bloodstream, was measured. The test computes the difference in partial pressure 
between inspired and expired carbon monoxide; a small difference implies a low 
diffusing capacity, which may be caused by either restrictive or obstructive 
conditions. In the context of sarcoidosis, a significant decrease in DLCO may be 
indicative of more severe disease, e.g. with signs of pulmonary fibrosis (226).  
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As indicated by the table listings of patient data for the individual studies in this 
thesis, a reduction in DLCO is more frequently observed in non-LS patients, who 
also have a higher risk of developing chronic disease and permanent tissue 
remodelling. 
 
Figure 10 | Lung volumes measured during static spirometry. The measurement of the volume 
of air that can be in- and exhaled during a given time is an important indicator of lung function, 
and for identification of breathing patterns that may be indicative of pathogenic conditions. Total 
lung capacity (TLC) represents the volume in the lungs at maximum inflation. It is equivalent to 
the sum of vital capacity (VC), which is the volume of air exhaled after the deepest inhalation, and 
residual volume (RV), corresponding to the air remaining in the lungs after maximal exhalation. 
 
 
Figure 11 | Air flow and dynamic lung function parameters in the healthy lung, obstructive 
and restrictive disease. Red lines indicate the patterns of air flow and forced expiration in three 
different conditions, with blue lines offering a comparison to the situation in a healthy individual. 
TLC, total lung capacity; VC, vital capacity; RV, residual volume; FEV1, forced expiratory volume in 
1 s; FVC, forced vital capacity. 
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3.2.3 Whole blood, serum and peripheral blood mononuclear cells 
Whole blood was collected from patients and healthy volunteers into sodium-
heparinised tubes prior to bronchoscopy. Serum was isolated as part of the clinical 
routine investigation, immediately frozen and stored at -80°C prior to use for 
enzyme-linked immunosorbent assay (ELISA) (Paper V). Peripheral blood 
mononuclear cells (PBMCs) were isolated by Ficoll-Paque density gradient 
separation according to established protocols (184), and used as internal controls 
for patient-matched BALF cells in emulsion PCR (Paper IV). For Paper II, flow 
cytometry was run on whole blood following initial lysis of erythrocytes. 
 
3.3 FLOW CYTOMETRY (PAPERS I-V) 
Flow cytometry is a laser-based technique enabling simultaneous detection of 
various cellular components at the single-cell level, and identification of rare cell 
populations from a complex sample. In short, cells in solution are labelled with 
monoclonal antibodies coupled to fluorescent dyes and passed through a liquid 
stream under high pressure, allowing analysis of thousands of particles per second. 
Laser-mediated excitation of antibody-bound fluorochromes results in light 
emission at different (longer) wavelengths, which is captured by detectors, called 
photomultiplier tubes (PMT), placed around the stream. PMTs convert light into 
electrical signals that can then be digitalised and displayed as “fluorescence 
intensity”. To avoid false positive detection of light “spill-over” from one emission 
channel to the next, a compensation setup is performed, where PMT voltage 
adjustment allows for maximum separation of positive and negative cell 
populations for each individual fluorochrome. In addition to the assessment of 
fluorescently labelled extra- and intracellular markers of choice, detectors parallel 
with the light beam measure forward scatter (FSC), which is proportional to cell 
size. In combination with side scatter (SSC), which is obtained by detectors placed 
perpendicularly to the stream and constitutes a measure of cell granularity, these 
two parameters offer the ability to discriminate major cell populations even in 
absence of additional labels. Furthermore, FSC and SSC can also be used to detect 
disproportionality between cell size and cell signal, aiding in discrimination of 
doublets, i.e. when more than one cell passes through the detector beam at the 
same time. The voltage pulse generated when a cell is excited by a laser is 
processed into three parameters: height (H), the maximum signal of a specific cell, 
which will change with adjustments in PMT voltage; width (W), the duration of the 
signal and a direct correlate of cell size, which is not affected by PMT voltage; and 
area (A), calculated from all H measurements made throughout the time (W) of cell 
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passage through the laser beam. Correlation of either FSC-A vs. FSC-H, FSC-H vs. 
FSC-W or SSC-H vs. SSC-W readily shows whether or not the electric signal of a 
cell is proportional to its size, positioning all singlet events on a diagonal display 
while doublets deviate from the 45° line, thus facilitating their exclusion from 
further analysis. 
 
For all studies, the percentage of CD4+ and CD8+ CD3+ T cells, respectively, as well 
as the percentage of Vα2.3+Vβ22+ CD4+ CD3+ T cells, in BALF of sarcoidosis 
patients and healthy individuals were measured by triple-laser, eight-colour flow 
cytometry using either a FACSCanto II, a FACSVerse, or a Fortessa X-20 (all 
supplied by Becton-Dickinson). As previously mentioned, a CD4/CD8 ratio >3.5 is 
considered a strong diagnostic indication for sarcoidosis. An expansion of TCR-
specific cells was defined as a more than three-fold increase compared to the 
median frequency of the same TCR variable segment in peripheral blood of healthy 
individuals. For Vα2.3+ T cells, this limit was set to >10% of all CD4+ T cells in the 
lung (227); for Vα2.3+Vβ22+ CD4+ T cells, to >0.5% (184). To adjust for spectral 
overlap between fluorochromes, compensation setup was performed using positive 
and negative compensation beads, as well as manual correction for varying 
degrees of BALF cell autofluorescence in individual samples. Singlets were 
identified through gating on FSC-A vs. FSC-H. Data analysis was performed using 
FlowJo X software. 
 
In Paper I, the above-mentioned markers were complemented with CD69, a marker 
of T cell activation (228) and tissue-resident memory cells (187, 229), and CD27, a 
marker of T cell differentiation (186). 
 
In Paper II, panels were designed to investigate CD4+ T cell subsets and possibly 
multifunctionality. “Master” transcription factors T-bet (TH1), RORγT (TH17) and 
FoxP3 (TREG) were complemented by chemokine receptors CXCR3 (TH1), CCR6 
(TH17) and CCR4 (TH2), as well as intracellular proliferation marker ki-67 and 
canonical cytokines IFNγ (TH1) and IL-17A (TH17). In this study, all markers were 
applied on cells from both BALF and whole blood derived from the same patient. A 
live/dead marker designed for intracellular staining was included in all panels for 
discrimination of viable cells. 
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For Papers III-V, CD4/CD8 ratio and TCR expression were evaluated as described 
above, prior to more comprehensive analysis by mass cytometry, emulsion PCR, 
and anti-vimentin antibody ELISA, respectively (detailed below). 
 
3.4 TRIPLE-COLOUR FLUOROSPOT (PAPER II) 
FluoroSpot is an extension of the ELISpot technology (230), facilitating 
measurement of cytokine-producing cells in solution following specific antigen 
and/or polyclonal stimulation. In summary, the method is based on the addition of 
cells and stimuli to a low-fluorescent polyvinylidene difluoride (PVDF) membrane 
pre-coated with cytokine-specific monoclonal antibodies. Upon stimulation, cells 
produce cytokines that diffuse into the membrane, forming spots. Each cytokine-
producing cell is thereby detectable as a single spot following addition of 
secondary antibodies and visualisation in a specialised reading instrument, 
allowing for quantification of spot numbers in stimulated samples versus 
unstimulated controls. While ELISpot is restricted to the measurement of a single 
cytokine at a time, FluoroSpot utilises fluorescently labelled secondary antibodies, 
enabling simultaneous detection of up to three cytokines, as well as identification 
of cells producing more than one type of cytokine. In Paper II, FluoroSpot kits and 
monoclonal antibodies developed by Mabtech AB were used for concomitant 
detection of IFNγ, IL-2, IL-17A, IL-10 and IL-22 production by BALF cells 
stimulated with anti-CD3/anti-CD28, which specifically target T cells. 
Visualisation and analysis was performed using an AID SpectrumReader and 
ELISpot v.7.0 iSpot software supplied by Autoimmun Diagnostika GmbH. The basic 
assay principle is depicted in Fig. 12. 
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Figure 12 | Triple-colour FluoroSpot. Stepwise depiction of the FluoroSpot procedure, showing 
simultaneous coating of ethanol-treated PVDF membrane plates with three cytokine-specific 
monoclonal capture antibodies, followed by addition of cells and stimuli. After a suitable 
incubation time to allow for cytokine production, detection is performed in two sequential steps 
using secondary tag-labelled or biotinylated detection antibodies. Subsequent binding of 
fluorescently labelled anti-tag antibodies and streptavidin conjugates recognising biotin serves to 
amplify the detection signal. Final analysis is performed on dried plates utilising an automated 
fluorescence reader with separate filters for detection of the different fluorophores (FITC, Cy3 and 
Cy5, respectively). 
 
3.5 MASS CYTOMETRY (PAPER III) 
By labelling of antibodies with elemental isotopes rather than fluorochromes, 
mass cytometry circumvents the impediment of spectral overlap that confines flow 
cytometric analysis to a fixed number of cellular markers per laser, and effectively 
combines the technologies of mass spectrometry and flow cytometry. In brief, 
following incubation with cells, these antibody-bound metal conjugates are 
nebulised and run through an argon plasma, converting them to ions that can be 
detected by a time-of-flight mass spectrometer. This technique thereby offers a 
unique possibility for analysis of a considerably higher number of individual 
markers on the same cell, making its use ideal for unbiased explorative studies. In 
Paper III, mass cytometry was run on a CyTOF2 mass cytometer provided by 
Fluidigm, using a set panel of 33 markers supplemented with antibodies targeting 
the Vα2.3/Vβ22 TCR. In addition to T cell-specific markers, the panel included 
separation of singlets from doublets by measurement of DNA content in relation 
to cell length, and Cisplatin for assessment of cell viability. Consecutive steps of 
mass cytometry are visualised in Fig. 13. 
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Figure 13 | Mass cytometry. Schematic flow-chart of the major steps involved in analysis of cells 
by mass cytometry, combining the technology of conventional flow cytometry with time-of-flight 
mass spectrometry. Cells are labelled with metal-conjugated antibodies, and samples in form of a 
liquid suspension are introduced into the instrument within a stream of argon gas, passing through 
a nebuliser to exit as aerosolised single-cell droplets. Resulting droplets are directed to the 
inductively coupled plasma-mass spectroscopy (ICP-MS) torch, undergoing successive 
vaporisation, atomisation and ionisation to generate an ion cloud, comprised of ions derived from 
both reporter metals and biological samples. Within the time-of-flight (TOF) mass analyser, ions 
are separated based on their mass-to-charge ratio and accelerated towards the detector. The 
quantity of each isotype, indirectly representing the expression of biological markers bound by 
metal-tagged antibodies, can thereby be determined for each individual cell. Data exported in the 
form of .fcs files are subsequently analysed using either routine flow cytometry analysis 
programmes, or more commonly, due to the high dimensionality and complexity of data, by multi-
parameter analysis methods such as t-distributed stochastic neighbourhood embedding (t-SNE), 
principal component analysis (PCA) or spanning-tree progression analysis of density-normalised 
events (SPADE). 
 
3.6 PCR, EPCR AND TCR SEQUENCING (PAPERS I AND IV) 
In Paper I, mRNA was extracted from BALF cells from HLA-DRB1*03+ sarcoidosis 
patients, either following initial fluorescence-activated cell sorting (FACS) on 
Vα2.3+Vβ22+ CD4+ T cells, or on bulk BALF. cDNA was generated and amplified by 
polymerase chain reaction (PCR) using primers for the Vα2.3 and Vβ22 TCR 
segments, respectively, in separate reactions. PCR products were then subjected to 
Next-Generation Sequencing (NGS), analysing the nucleotide sequences of the 
highly variable CDR3 segment, which is the region primarily involved in antigen 
binding. While a high degree of clonality of these cells could be established due to 
the remarkably low number of CDR3 sequences responsible for the vast majority of 
reads, as Vα2.3 and Vβ22 were assessed separately, the exact structure of the 
complete αβ TCR could not be determined. Therefore, an alternative approach was 
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applied in Paper IV, where CD4+ T cells were sorted from HLA-DRB1*03+ BALF and 
blood samples and whole TCR cDNA generated by emulsion PCR (ePCR) (231). 
Briefly, the first PCR step of a three-part reaction sees single cells immersed in 
individual oil emulsion droplets, with the addition of primers covering the entire 
range of TCR V segments and being designed for extension overlap. Through 
emulsion-mediated seclusion, cDNA from full αβ TCRs can be generated from 
single cells. After the emulsion is broken following termination of the first PCR 
reaction, blocking oligonucleotides are added for the second round of 
amplification, to ensure that only joint αβ sequences, and not unbound α’s or β’s, 
are further amplified. The final PCR introduces unique combinations of primers 
for each sample as barcodes for Illumina sequencing. The full TCR sequence is 
instrumental in the search for antigenic targets, and the identified CDR3 
consensus sequences presented in Paper IV will serve as a foundation for 
generation of T cell hybridomas and subsequent screening against peptide 
positional scanning libraries (described below). A schematic overview of the ePCR 
procedure is shown in Fig. 14.  
 
Figure 14 | Emulsion PCR. Stepwise depiction of the ePCR principle, showing immersion of single 
cells into emulsion droplets for subsequent extraction of TCR Vα and Vβ mRNA in a single-cell 
manner. Reverse transcription of mRNA into cDNA and subsequent amplification with extension 
overlap occurs within each droplet, ensuring that only TCR α and β chains expressed on the same 
cell are combined into cDNA molecules. Following extraction and DNA purification, nested 
amplification of fused TCR αβ cDNA is performed during a second round of PCR. The addition of 
blocking oligonucleotides ensures that free, non-fused α and/or β molecules are not amplified. A 
third round of PCR involves bar-coding for sequencing using unique primer combinations for each 
individual sample. The final PCR product is assessed on an agarose gel prior to submission for 
Illumina paired-end sequencing, the results of which are analysed to elucidate intra- and inter-
patient recurrence of CDR3 sequences for the combined TCR α and β chains. 
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Importantly, while the NGS analysis in Paper I was selectively performed on the 
Vα2.3 and Vβ22 TCR segments, ePCR data in Paper IV was generated in an 
unbiased fashion, with all variable αβ TCR segments included in the sequencing 
process. Notably, the preferential association of Vα2.3 with Vβ22 and vice versa in 
HLA-DRB1*03+ patients could be confirmed by ePCR, enforcing the role of these 
cells in sarcoidosis immunopathology and presumably antigen recognition. 
 
3.7 T CELL HYBRIDOMA GENERATION AND PEPTIDE LIBRARY SCREENING 
(PAPER IV AND BEYOND) 
A T cell hybridoma is assembled by the insertion of a plasmid vector carrying the 
human TCR sequence of choice into an immortalised mouse cell line lacking 
innate TCR expression. This allows repeated stimulation assays to be performed 
using the same patient-derived TCR, but without the risk of depleting scarce 
clinical samples. Hybridomas are co-cultured with candidate peptides and APCs 
expressing HLA molecules of interest (in this case HLA-DRB1*03), preferably using 
Epstein-Barr virus (EBV)-transformed syngeneic PBMCs. Ten amino acid residue-
long peptides, so-called decapeptides, are generated through sequential 
randomisation of residues where one position is always fixed, and other positions 
vary. Responsiveness of hybridomas to individual peptides is evaluated by means 
of an ELISA measuring IL-2 production. Combined data from screening of all 
peptide groups can then be used to deduce which amino acid is most likely to 
appear at which position, forming complete peptide sequences, here termed 
“mimotopes”, which can be used as stimuli to test reactivity of primary patient 
cells. Ultimately, database comparison of mimotope sequences with those of 
microbial, environmental or self-derived proteins can facilitate discovery of 
biologically relevant antigenic candidates for further investigation. Fig. 15 
outlines the experimental rationale for ePCR and ensuing experimental steps, 
including hybridoma generation and peptide library screening. 
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Figure 15 | Application of ePCR in T cell hybridoma generation and peptide library 
screening. The ePCR procedure constitutes a crucial first step in the ongoing process of 
determining peptide antigen specificity of CD4+ T cells expressing the Vα2.3/Vβ22 TCR. Identified 
TCR Vα and Vβ CDR3 consensus sequences are introduced via a bacterial expression vector into 
immortalised murine T cell hybridomas lacking innate TCR expression. Hybridomas expressing 
human TCRs of interest are then co-cultured with APCs expressing HLA-DRB1*03 and 
decapeptides from a positional scanning library. Each of the ten sublibraries has one position fixed 
(O), while the others vary (X). Within each sublibrary, the fixed position can be any of the twenty 
known amino acids. Each sublibrary thus comprises 3.2 x 1011 different peptides, with a total of 6.4 
x 1012 peptides in the complete library. Stepwise identification of preferred amino acid residues at 
each position generates “mimotope” sequences that can be used for identification of biologically 
available candidate antigens with similar properties, and subsequent stimulation tests on primary 
patient cells. 
 
3.8 ANTI-VIMENTIN ANTIBODY ELISA (PAPER V) 
Presence of e.g. proteins, peptides, antibodies or hormones in bodily fluids can be 
readily assessed by ELISA, where the antigen of interest is immobilised on a solid 
surface, commonly a polystyrene microtiter plate, either by direct adsorption to 
the surface or via capture by a specific antibody. Linkage of secondary antibodies 
to an enzyme enables detection of the target antigen by addition of an enzymatic 
substrate in the final step. Enzymatic activity generates a detectable signal, 
usually observed as a colour change in the plate and measured as optical density, 
which is relative to the quantity of antigen in the sample. In Paper V, the 
occurrence of IgG and IgA antibodies specific for the cytoskeletal protein 
vimentin, identified as a potential antigenic candidate in Paper I and preceding 
studies (116, 158), in BALF and serum from sarcoidosis patients and healthy 
controls was evaluated using an ELISA developed in-house at the University of 
Chicago (163). In all samples, antibody reactivity towards the full-length protein, 
as well as towards two amino (N)-terminal and one carboxyl (C)-terminal 
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truncations of vimentin, was measured. Subsequent correction for total IgG or IgA 
concentration yielded absolute concentrations of anti-vimentin antibodies (AVAs) 
in the same sample, which could be correlated to clinical or immunological 
parameters, such as HLA carriage, CD4/CD8 ratio, percentage of BALF Vα2.3+Vβ22+ 
CD4+ T cells, or lung function. 
 
3.9 IMMUNOFLUORESCENCE MULTI-COLOUR CONFOCAL MICROSCOPY 
(PAPER V) 
Immunofluorescence microscopy is a powerful tool for visualisation of cells and 
extracellular components in tissue, and offers the ability to study in situ cell-cell 
co-localisation and interaction as a complement to analysis of cells and secreted 
components in solution. For Paper V, paraffin-embedded mucosal biopsies 
containing granulomatous tissue from sarcoid lungs, as well as corresponding 
samples from non-granulomatous healthy lungs, were fixed onto microscopy 
slides and stained for presence of CD4+ T cells (using anti-CD3 and anti-CD4 
antibodies), B cells (anti-CD20), vimentin and active proliferation (anti-ki-67). 
Tonsil tissue, known to harbour large organised clusters of B and T cells, was used 
as a positive staining control. Images were obtained using an 40X oil immersion 
objective on a Leica SP8 Laser Scanning microscope with 1024 x 1024 fields of view 
and colour-converted using Image J freeware. 
 
3.10 STATISTICAL AND BIOINFORMATIC ANALYSIS 
For all studies, univariate statistical analysis was performed in GraphPad Prism 
software using non-parametric tests, unless equal inter-group variances could be 
determined using an F-test. Depending on the particular assay, one- or two-way 
analysis of variance (ANOVA) tests were used for comparisons between groups. 
For individual comparisons, the two-tailed Mann-Whitney U test was applied, 
along with Wilcoxon’s sign rank test for paired comparisons. Spearman’s rank test 
was used for correlation analyses. In all instances, p < 0.05 was considered 
significant. 
For Paper III, hierarchical cluster analysis of mass cytometry data was performed 
following manual gating on single, viable (DNA+, Cisplatin-) CD3+ CD4+ CD8- T 
cells. The Citrus algorithm (232) was used to identify CD4+ T cell populations of 
different abundance in LS and non-LS samples based on the collective expression 
across all investigated markers. A relatively high false discovery rate (FDR) of 
<0.25 was chosen to allow for detection of differential regulation despite the small 
cohort size. Clusters were visualised by ACCENSE (233) and complemented with 
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dimensionality reduction by the t-distributed stochastic neighbourhood 
embedding (t-SNE) algorithm (234), run in R and RStudio (235), respectively. 
 
3.11 TECHNICAL LIMITATIONS AND POTENTIAL STUDY BIAS 
Despite their high sensitivity and specificity, all experimental methods harbour 
innate limitations that must be adequately addressed for correct analytical 
assessment. The studies presented in this thesis have all been conducted on 
human primary cells derived from BALF and blood, as well as cell-depleted BALF 
and serum. The use of human samples constitutes a challenge in itself, due to 
limited availability of material and the impracticality of introducing multiple 
points of sampling, especially for invasive procedures such as bronchoscopy. Data 
interpretation must therefore be approached with caution, as results only 
represent a snapshot of the current state of disease. Consequently, clinical 
characteristics of individual patients, such as disease onset, specific organ 
manifestations or chest radiographic stage, should also be taken into 
consideration during analysis to form as accurate and complete an image of the 
present immunological state relative to symptomatic presentation as possible. In 
sarcoidosis, routine HLA typing of patients is of particular importance due to the 
known influence of certain HLA alleles on disease presentation and outcome, and 
can provide essential information when combined with both molecular and clinical 
data. Conversely, HLA carriage can also introduce sampling bias, if disregarded 
during clinical assessment. Likewise, internationally, sarcoidosis patients are 
commonly treated as a single group contrasted to healthy individuals. In such 
case, the overarching discrepancy between the healthy and the inflamed lung may 
conceal true differences between patient subgroups that could be essential for 
prognostic evaluation or treatment indication, as well as for insights into 
molecular mechanisms of disease. 
 
As previously mentioned, the main drawback of flow cytometry is its restriction to 
a fixed number of detectable fluorochromes per laser in the instrument, due to 
overlap of fluorochrome emission spectra, and thus an increasing need for 
compensation controls. The more markers included, the more difficult it therefore 
becomes to separate individual populations, especially when striving to analyse 
multiple markers present on the same cell. In the specific context of tissue-
resident cells, it should also be noted that both flow cytometry and FluoroSpot 
analysis are further complicated by the intrinsic autofluorescence of alveolar 
macrophages, which constitute the dominant population in BALF. In contrast, 
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mass cytometry abolishes the need for extensive compensation measures, as the 
vaporisation of metal isotopes and subsequent detection of released ions do not 
cause any spectral overlap (Fig. 16). However, this relatively new technique is still 
limited by its demand for higher cell numbers (complicating its application on rare 
clinical samples), lower flow rate and thereby longer analysis time, more complex 
experimental procedure, and higher running costs, effectively making it 
unattainable for most average-sized laboratories. In comparison, flow cytometry 
offers higher sensitivity per individual marker, which is useful for focused analyses 
of already known study targets, while mass cytometry has the capacity to evaluate 
higher numbers of markers at the same time, enabling broader discovery studies of 
hitherto unknown molecular features. Notably, the sheer amount and complexity 
of data obtained from mass cytometric analyses set higher demands on 
computational processing. As life science becomes increasingly concerned with 
handling of large datasets, coming generations of scientists will likely be more 
diligently trained in bioinformatic approaches, in addition to laboratory 
methodology and biomedical theory. As yet, however, these skills are rarely found 
in combination, requiring collaborative efforts and potentially introducing 
difficulties in scientific communication, as well as interpretation of data from a 
clinically and biologically relevant perspective. 
 
Figure 16 | Antibody-mediated detection in flow and mass cytometry. Simplified comparison 
of the underlying principle of antibody-mediated detection of cellular markers in flow and mass 
cytometry, respectively. While flow cytometry is limited by the need for fluorescence compensation 
due to spectral overlap between antibody-coupled fluorochromes, the mass cytometer allows for 
collection of mass spectral data in distinct channels separated by as little as one atomic mass unit. 
Through discrimination of isotopes with minimal overlap, mass cytometry vastly increases the 
number of markers that can be assessed simultaneously on a single cell. 
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Compared to flow cytometry, FluoroSpot offers detection of cytokine-producing 
cells with even higher sensitivity. Moreover, all cytokines produced throughout 
the course of incubation will be captured in the membrane and detected at the 
conclusion of the assay. This setup facilitates detection not only of early-response 
cytokines, but also of those where production is initiated later and therefore does 
not reach as high quantities within the same time frame. In contrast, cellular 
toxicity of protein-transporter blocking agent brefeldin A, which inhibits cytokine 
release from the cell and enables detection by intracellular staining, prevents cells 
subjected to analysis by flow cytometry from being kept in culture for extended 
periods of time (>18 h). This diminishes the time window for cytokine production, 
complicating analysis of late-response cytokines or cytokines produced in 
extremely low amounts. However, while flow cytometry allows for identification 
and further characterisation of the cells responsible for cytokine production by 
inclusion of additional markers in the analysis panel, FluoroSpot provides no 
means of further defining the cells, except for their responsiveness to e.g. T cell-
specific stimuli. Direct quantitative comparisons between the different methods 
are therefore not possible, and they should rather be considered as complementary 
to one another. In Paper II, FluoroSpot was primarily used to demonstrate 
presence of a broader range of cytokines and in larger quantities than was possible 
to obtain by flow cytometry, while concomitant transcription factor and cytokine 
expression was deduced by the latter. In both cases, however, it is important to 
remember that different polyclonal stimuli will preferentially induce particular 
cytokine responses (236), which could potentially affect data interpretation. 
 
Comparative studies of B and T cell responses, as highlighted by Paper V, are 
complicated by the inherent immunological differences between the two cell 
types. While T cell specificity is generally highly restricted to a few discrete HLA-
peptide combinations, B cell responses are more multivalent, and multiple B cell 
clones producing antibodies with cross-reactive specificities are likely to expand in 
parallel in response to the same antigenic trigger. The presence of such cross-
reactive antibodies is difficult to judge by means of an ELISA, and the correlation 
analyses made between humoral and cellular responses must therefore be 
considered as indicative of a joint B and T cell response, rather than directly 
quantifiable. In addition, tissue analysis by microscopy is, although highly 
informative, a largely non-quantitative approach, especially when applied to a 
limited set of samples, and mainly serves a visual purpose. Nevertheless, the 
observation of co-localised, proliferating B and T cells with extracellular vimentin 
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in the vicinity of sarcoid granulomas especially in HLA-DRB1*03+ patients, but less 
so in HLA-DRB1*03- individuals and not in healthy lung tissue devoid of 
granulomatous structures, is highly suggestive of a coordinated antigen-driven 
response involving both branches of the adaptive immune system. Microscopy in 
this regard offers a valuable insight into the B cell compartment, which is not 
routinely considered due to the low numbers of B cells present in BALF, and 
complements the functional analysis of antibody production. 
 
In summary, the use of several distinct, but reciprocal, methods is highly 
advisable, especially in translational science where human material is scarce and 
inter-patient variability is high. As evidenced by this thesis, the ability to confirm 
and expand on findings from one study in another using alternative techniques – 
exemplified by the identification of expanded Vα2.3+Vβ22+ CD4+ T cells in BALF of 
HLA-DRB1*03+ patients by flow cytometry in Paper I and ePCR in Paper IV, the 
cytokine analyses performed with flow cytometry and FluoroSpot in Paper II, or 
the revelation of retained regulatory capacity of CD4+ T cells in LS compared to 
non-LS, supported by elevated IL-10 production in Paper II and expression of 
CTLA-4 and PD-1 in Paper III – strengthens the working hypotheses and 
highlights the benefit of performing validation experiments on the same cohort, as 
to extract as much information as possible from valuable clinical samples. For the 
research field as a whole, this also infers that although all methods are not 
available to all laboratories, studies can still be compared on a global level, as long 
as inclusion/exclusion criteria for patients are clearly accounted for. 
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4 RESULTS AND DISCUSSION 
This section offers a short summary of the results of the individual studies, which 
are discussed separately and in more detail in the respective papers. Subsequent 
reflections on the collective findings of the entire thesis follow the red thread of 
antigen discovery and immunological differences between clinical phenotypes, 
and strive to provide a foundation for future research. 
 
4.1 MAIN FINDINGS 
4.1.1 Paper I 
In the lungs of HLA-DRB1*03+ patients with sarcoidosis, and most frequently LS, 
an accumulation of CD4+ T cells expressing the Vα2.3/Vβ22 TCR was observed 
during active disease. These cells expressed high levels of CD69, which is an early 
marker of T cell activation following engagement of the TCR/CD3 complex in 
response to antigen (228). In addition, more recent studies have found CD69 to be 
one of the defining traits of tissue-resident memory cells (229). In this study, 
Vα2.3+Vβ22+ CD4+ T cells expressed higher levels of CD69 than their CD4+ T cell 
counterparts that did not express this TCR. Moreover, Vα2.3+Vβ22+ CD4+ T cells 
showed markedly reduced expression of CD27, the expression of which is lost upon 
prolonged antigen exposure (186). TCR sequencing of the Vα2.3 and Vβ22 
segments separately revealed only a few (<5) individual CDR3 sequences per 
patient, with identical or near-identical sequences being observed in different 
patients, and recurrence of certain charged amino acid residues at specific 
positions known to influence antigen binding. Together, these characteristics 
indicate a high degree of clonal expansion, in line with antigen-specific responses. 
Finally, a molecular 3D model of the TCR Vα2.3/Vβ22-HLA-DRB1*03 complex was 
generated based on the sequencing results. A peptide derived from the C-terminal 
end of the cytoskeletal protein vimentin was found to fit into the peptide-binding 
cleft, with connecting points towards all four HLA binding pockets, as well as the 
CDR3 loop of the Vβ22 chain, thus implicating vimentin as a potential autoantigen 
in sarcoidosis. 
 
4.1.2 Paper II 
CD4+ T cells simultaneously expressing transcriptional regulators T-bet, 
associated with TH1 responses, and TH17 counterpart RORγT, were identified in the 
lungs, but not peripheral blood, of both sarcoidosis patients and healthy 
individuals. Frequencies of T-bet+RORγT+ cells were significantly higher in disease, 
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and especially in LS patients. In contrast, no differences were observed between 
the groups in terms of FoxP3 expression, and almost all FoxP3+ cells were also 
positive for T-bet, indicating a selective regulation of TH1-driven inflammation 
(36, 237), alternatively a transient upregulation of FoxP3, which has frequently 
been observed during effector T cell activation (34). In addition, concomitant 
expression of chemokine receptors CXCR3 and CCR6, but not CCR4, was elevated 
in the lungs compared to peripheral blood. T-bet+RORγT+ cells showed a markedly 
higher proliferative capacity, represented by expression of ki-67, which stains 
actively cycling cells, compared to T-bet-RORγT- cells. Vα2.3+Vβ22+ CD4+ T cells 
co-expressed T-bet and RORγT, as well as CXCR3 and CCR6, to a higher degree 
than CD4+ T cells negative for this TCR. Moreover, T cells from LS patients 
produced a broader range of cytokines than non-LS T cells, with a higher 
percentage of cells producing IL-10, IL-17A, IL-2 and IL-22. In contrast, IFNγ 
production was significantly higher in non-LS T cells. T-bet+RORγT+ cells were 
able to produce IFNγ, IL-17A or both, and higher frequencies of these double-
positive multifunctional cells correlated with non-chronic disease, suggesting a 
prominent role in tissue homeostasis and disease outcome. 
 
4.1.3 Paper III 
Building on to Paper II, a more comprehensive assessment of BALF CD4+ T cells 
was achieved through mass cytometry and hierarchical cluster analysis. Nineteen 
CD4+ T cell populations differing significantly in abundance between HLA-
DRB1*03+ LS and HLA-DRB1*03- non-LS patients were identified. Most 
prominently, LS clusters were defined by higher expression of regulatory receptors 
CTLA-4 and PD-1, as well as ICOS, while non-LS cells consistently showed higher 
expression of effector and activation markers HLA-DR, CD127 and CD39. 
Moreover, expression of adhesion molecule CD44 was consistently reduced in 
CD4+ T cells from LS patients. Vα2.3+ CD4+ T cells demonstrated functional 
heterogeneity with expression of multiple inhibitory and/or co-stimulatory 
molecules, some of which appeared linked to co-expression of the Vβ22 TCR 
segment, or of other Vβ variants. Lastly, as shown by a near-complete overlap of 
CD8 and ki-67, CD8+ T cells were discovered to proliferate to a markedly higher 
degree than CD4+ T cells, suggesting active CTL involvement in disease 
progression. 
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4.1.4 Paper IV 
As a follow-up to Paper I, ePCR was used for unbiased identification of joint TCR α 
and β chains from single CD4+ T cells and the dominant αβ pairs associated with 
disease. The preferential pairing of Vα2.3 and Vβ22 in HLA-DRB1*03+ LS patients 
observed by flow cytometry was confirmed by ePCR, as was the recurrence of 
specific CDR3 sequences within and between patients, but not in HLA-DRB1*03- 
patients or controls. From this, both TCR α and β consensus sequences could be 
identified, constituting an important step forward in the search for candidate 
antigens that can be recognised by the Vα2.3/Vβ22 TCR, and for the first time 
providing a means of, within the scope of future studies, generating T cell 
hybridomas expressing entire patient-derived TCRs. 
 
4.1.5 Paper V 
Paper I hypothesised that a vimentin-derived peptide could act as a T cell 
autoantigen, which, together with the previously identified involvement of 
vimentin in B cell-mediated autoimmune diseases such as SLE and RA, prompted 
investigation of the B cell and anti-vimentin antibody repertoire also in 
sarcoidosis. This revealed higher IgG and IgA AVA titres in sarcoidosis patients 
compared to healthy controls, and markedly higher concentrations in BALF 
compared to blood. Moreover, AVA titres correlated with established diagnostic 
criteria such as CD4/CD8 ratio and percentage of Vα2.3+Vβ22+ CD4+ T cells in 
BALF. Stratification of AVAs by target region, more specifically two N- and one C-
terminal fractions, revealed a relatively higher degree of N-terminal-specific 
antibodies in healthy individuals, while HLA-DRB1*03+ patients showed a shift 
towards C-terminal reactivity. Furthermore, HLA-DRB1*03- patients presented 
with higher total Ig levels, but lower concentrations of specific AVAs, while the 
opposite was true for HLA-DRB1*03+ patients. In the inflamed lung, extracellular 
vimentin was readily detected, and co-localised with T and B cells in the vicinity of 
granulomatous structures. Proliferation, as marked by ki-67 expression of both T 
and B cells, was again more pronounced in HLA-DRB1*03+ patients. Together, this 
is indicative of a coordinated antigen-specific T and B cell response to vimentin in 
HLA-DRB1*03-mediated sarcoidosis. 
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4.2 DISCUSSION 
4.2.1 The lung microenvironment promotes a TH1/TH17 phenotype that is 
augmented in sarcoidosis 
While the strive to simplify nature as far as possible to better understand its 
complexity is a characteristic human trait, biological systems are built on dynamic 
processes and are therefore not readily classified into black-or-white scenarios. 
The emerging concept of T cell plasticity is the most recent example of how nature 
“fails” to conform to man-made definitions, and recent years have even revealed 
the existence of cells simultaneously expressing markers formerly believed to be 
unique for completely separate immunological compartments, e.g. “T cells” 
positive for both T cell co-receptor CD3 and B cell marker CD20 in MS (238). 
Indeed, the escalating number of more or less established subsets, distinguished 
only by subtle differences and repeatedly classified differently depending on the 
study conducted, may actually complicate rather than facilitate interpretation of 
the role of these cells in health and disease. Essentially, the notion of plasticity in 
itself means that subsets cannot be strictly defined over time, but only at the 
specific moment of sampling. In the context of human immunology, this is of 
particular importance as cells cannot be constantly monitored in vivo throughout 
their lifespan, or, consequently, throughout the course of disease. 
 
Several studies conducted on peripheral blood have used combinations of 
chemokine receptors to define T cell subsets (194), but these definitions cannot 
readily be applied to tissue-resident cells. Chemokine receptors direct migration to 
the target organ where the cell will perform its designated function, and it is only 
reasonable that innate chemokine receptor expression of T cells will differ 
between tissue compartments even at steady-state. As evidenced by Paper II, a 
majority of CD4+ T cells in both sarcoidosis patients and healthy individuals were 
found to express both TH1-associated chemokine receptor CXCR3 and TH17 
equivalent CCR6 in BALF, but not in peripheral blood. This correlated well, but not 
perfectly, with expression of transcriptional regulators T-bet (TH1) and RORγT 
(TH17) in the lung. A similar discrepancy between the lung and circulation in terms 
of chemokine receptor expression has been shown by Ramstein and colleagues 
(193), where TH subset definitions were based solely on chemokine receptor, and 
not transcription factor, expression. Notably, the presence of ~25% “TH1/TH17” 
hybrid cells also in healthy subjects suggests the situation in the sarcoid lung to be 
a mere extension of what is observed under homeostatic conditions. In Paper II, 
patients with non-chronic disease were found to present with higher frequencies 
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of T-bet+RORγT+ CD4+ T cells compared to patients with chronic disease, further 
emphasising that these cells are not necessarily “pathogenic” in themselves. For 
instance, Lexberg et al previously argued that the combined effector repertoires of 
TH1 and TH17 cells might confer a physiological advantage at the single-cell level, 
and that such cells could be more efficient in orchestrating disease resolution 
(239). Importantly, however, a majority of the non-chronic patients in Paper II 
were diagnosed with LS, while the opposite was true for the chronic disease group. 
It still remains to be elucidated whether LS patients do have a better prognosis due 
to higher efficiency and differential functionality of TH1/TH17 cells, or whether LS 
and non-LS simply constitute two discrete, albeit similar, disease conditions that 
ought to be considered separately, with different factors contributing to disease 
presentation and outcome (some of which are discussed in the following sections), 
thus also influencing a discrepancy in TH1/TH17 polarisation and balance. 
 
Nevertheless, in Crohn’s disease, a granulomatous disorder affecting the gut, 
inhibition of IL-17A has been shown not to ameliorate, but rather to exacerbate 
inflammation (240), suggesting a protective effect of this cytokine and an overlap 
of TH1, TH17 and TREG functionality in T cells residing in mucosal tissues. Instead, 
IFNγ may be the primary culprit in driving pathogenic processes (241). Secretion 
of IL-17A and IL-22 in the healthy gut (20) further highlights that more detailed 
investigation into immunological features of the healthy lung are strongly 
warranted. In addition, both these cytokines have been shown to have protective 
effects during Mycobacterium tuberculosis-induced granulomatous inflammation 
(242), and reduced IL-22 levels have been observed in patients with chronic 
sarcoidosis and IPF (21). Comprehensive investigation of functional parameters 
such as IL-23R expression on CD4+ T cells would be worthwhile, as IL-23 appears 
to be a key facilitator of pro-inflammatory TH17 responses (243). In its absence, 
RORγT+ CD4+ T cells can produce IL-10 and act to restrain inflammation (244). 
Genetic analysis have found profiles associated with the TH17 and TH22 
differentiation pathways in LS, but not non-LS patients (95), and in Paper II, T 
cells from LS patients were observed to produce higher amounts of cytokines 
involved in immune regulation and mucosal homeostasis, most prominently IL-10, 
IL-22 and IL-17A. In contrast, non-LS T cells produced mainly IFNγ. Together, this 
strengthens the hypothesis that a combined TH1/TH17 response is central to 
pulmonary immunology, and that this response is enhanced in LS patients, but 
somehow skewed towards a more aggressive “TH1-only” phenotype in non-LS 
patients. Accordingly, it is possible that the TH1/TH17-mediated pathogenicity 
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observed in e.g. RA, MS and psoriasis (13-17) is driven primarily by excessive IFNγ 
secretion, and that the pro- or anti-inflammatory functions of IL-17A are strongly 
dependent on the local tissue microenvironment. 
 
4.2.2 Disease outcome depends on CD4+ T cell balance 
Although of major interest for understanding immune homeostasis in the lung, 
the current studies show that the TH1/TH17 paradigm alone cannot fully explain 
the course of disease. Paper III outlines the pulmonary CD4+ T cell compartment as 
highly dynamic, and reveals concomitant expression of several markers that may 
be of critical importance for disease outcome. Considering the entire CD4+ T cell 
repertoire as a whole provides further incentive for reassessment of the role of 
TREGs in sarcoidosis. Previous studies have reported elevated ICOS expression 
(200), as well as IL-10 production (201), in LS, suggestive of a more self-restrictive 
response, while in non-LS, a shift towards a purely effector-driven response seems 
to occur, exemplified e.g. by a reduction in T cell immunoglobulin mucin domain 
(TIM) molecules that have been proposed to negatively regulate TH1 responses 
(245). In Paper II, the latter is represented by high IFNγ production and in Paper 
III by consistently upregulated expression of activation markers HLA-DR, CD127 
and CD39. 
 
Reduced expression of CTLA-4 on CD4+ T cells in sarcoidosis compared to healthy 
individuals has been reported previously (145), and while only comprising one 
healthy control sample, Paper III confirmed this finding, as well as demonstrating 
a significant, further decrease in non-LS patients compared to LS. Retained  
CTLA-4 and PD-1 expression in HLA-DRB1*03+ LS patients, who are known to 
have a particularly good prognosis, expands on the notion that the balance 
between immune activation and regulation is central to sarcoid inflammation. 
This hypothesis is further supported by the observed development of sarcoid-like 
granulomatous disease in patients receiving anti-CTLA-4 or anti-PD-1 therapy for 
malignancy (146-150), suggesting that abolishing this immune-dampening 
function propagates sarcoid inflammation. While some studies have argued for 
increased PD-1 expression to associate with reduced CD4+ T cell proliferation and 
contribute to the pathogenicity of sarcoidosis in the context of an infection (246, 
247), the view of sarcoidosis as an autoimmune disorder suggests that therapeutic 
PD-1 blockade would be counterproductive, if not directly harmful. In this 
scenario, as suggested by Paper III, among others, PD-1 is instead likely to be 
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upregulated as a means of controlling an adaptive immune response to persistent 
tissue (self-)antigens that the patient is unable to clear (206). 
 
Moreover, these findings show that tissue-resident CD4+ T cells may have the 
ability to perform certain regulatory functions without being classified as “true” 
TREGs. In Paper II, this is exemplified by presence of proliferating T-bet+FoxP3+ 
CD4+ T cells in BALF, a phenotype that may be involved in lung-specific immune 
regulation and protection against harmful (auto)immune reactions. This, again, 
stresses the importance of distinguishing cells characterised in the circulation 
from cells active in their respective target organs. Indeed, in all studies in this 
thesis, as well as in previous reports and a mass cytometry pilot analysis 
comparing paired BALF cells and PBMCs from sarcoidosis patients, BALF CD4+ T 
cells emerge as markedly different, functionally and phenotypically, from their 
blood counterparts. In summary, these findings, and especially of Papers II and III 
in combination, highlight the importance of investigating all CD4+ T cells rather 
than stratifying by subset-specific factors, as this restricts the search window and 
skews the information obtained, particularly in a tissue-specific context. 
 
4.2.3 CD4+ T cells are not the sole drivers of sarcoid inflammation 
Not only are CD4+ T cells responsible for propagating inflammation, but also, 
especially in LS, for mediating resolution, most prominently through secretion of 
inhibitory cytokines and expression of regulatory co-receptors. However, emerging 
evidence from the constituent papers of this thesis and others argue for more 
prominent involvement of other cellular and humoral responses than previously 
acknowledged. Remarkably, Paper III revealed a surprisingly active proliferation in 
the CD8+ T cell compartment, while in comparison, CD4+ T cells demonstrated 
much lower proliferative capacity. Furthermore, Paper III identified elevated CD57 
expression in certain non-LS clusters, potentially reflecting T cells with a more 
advanced differentiation state, reduced replicative capacity but retained cytokine 
production, particularly of IFNγ (248-250), and cytotoxic functions (251). Given 
the recent observation that cytotoxic activity of CD8+ T cells is augmented in non-
LS patients (252), it is tempting to speculate that expression of regulatory 
receptors and secretion of inhibitory cytokines by CD4+ T cells act to restrict 
cytotoxic CD8+ T cell activity in LS lungs, while unrestrained CTL responses, 
including high IFNγ production, in non-LS effectively lead to chronic 
inflammation and persistent tissue damage. Indeed, it is possible that CD8+ T cells 
constitute a more important contributor to progressive non-LS inflammation than 
  54 
CD4+ T cells, as suggested also by consistently lower CD4/CD8 ratios in non-LS 
patients. 
 
In addition to CD8+ T cells, B cells have received scarce attention throughout the 
history of sarcoidosis research, despite being observed to undergo somatic 
hypermutation in the lungs and to localise around sarcoid granulomas (253), as 
well as to directly correlate with the percentage of T cells in BALF (254). However, 
their exceptional capacity for antigen uptake and presentation make them 
exceedingly interesting in the context of antigen discovery, as well as in 
development of novel diagnostic and prognostic tools. Although not included in 
Paper III, mass cytometry analysis also indicated simultaneous expression of 
CXCR5, PD-1 and ICOS, among others, all of which are markers traditionally 
associated with TFH cells. This suggests at least certain groups of CD4+ T cells to 
engage in active interaction with B cells, and, in reference to the previous section, 
provides further rationale for their maintained PD-1 expression. In Paper V, B cell 
proliferation was shown to be particularly pronounced in HLA-DRB1*03+ lungs, 
and to coincide with CD4+ T cell activity. Moreover, while the total 
immunoglobulin content in BALF was higher in HLA-DRB1*03- patients, the 
concentration of antibodies targeting specific vimentin epitopes was higher in 
HLA-DRB1*03+ individuals, mirroring the image derived from T cell research, of a 
more antigen-driven, efficient and less aggressive immune response in these 
patients. The involvement of B cells and particularly class-switched, antigen-
specific antibodies in sarcoid inflammation may be suggestive of memory 
development, although more detailed studies on B cell clonality, epitope 
specificity and surface markers are required to validate such statements. 
Intriguingly, in LS patients, disease recurrence years after complete clinical 
remission is only seen in HLA-DRB1*03+ individuals (93), pointing to both a 
superior capacity for antigen clearance, but also possibly development of long-
lived (self-)memory responses in these patients, such as has been demonstrated 
e.g. in experimental models of SLE (255, 256). Monitoring the AVA status of such 
patients during active disease, remission and potential relapse would therefore be 
most interesting in terms of prognostic assessment. Another notable observation, 
for continuity omitted from Paper V, was the significantly higher concentrations 
of AVAs in women compared to men. As female LS patients more frequently 
present with erythema nodosum (92), which is considered to be an immune 
complex-mediated condition (257), higher autoantibody titres in females might 
contribute to gender differences in symptomatic presentation. Together with the 
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gender-specific patterns of disease onset (71), this could provide further rationale 
for investigation of distinct pathogenic pathways in males and females. 
 
4.2.4 Potential differences in granuloma formation and persistence between 
LS and non-LS 
In Paper III, expression of adhesion molecule CD44 on CD4+ T cells was found to 
differ significantly between HLA-DRB1*03+ LS and HLA-DRB1*03- non-LS 
patients, with T cells from LS patients expressing markedly lower levels compared 
to non-LS. CD44 exists in several isoforms due to alternative splicing and 
posttranslational modifications, and mediates adhesion to the endothelium and 
extracellular matrix. Its expression on lymphocytes in pulmonary sarcoidosis, as 
well as other mucosal disorders such as Crohn’s disease, has been speculated to 
influence their homing and activation, in addition to stimulating macrophage 
differentiation (258). Furthermore, elevated levels of soluble CD44 have been 
demonstrated in conditions with an autoimmune background, including 
sarcoidosis (259, 260), suggesting involvement also in cell-cell communication. 
Oddly, few, if any, studies have been explicitly dedicated to identifying differences 
between sarcoidosis phenotypes with regards to the actual granuloma. As LS to a 
large extent is characterised by spontaneous resolution, any subtle variability in 
granuloma formation and maintenance could be of clinical relevance. Recently, 
Linke et al discovered increased activity of mechanistic target of rapamycin 
(mTOR) complexes in sarcoid granulomas of patients with active progressive 
disease, compared to patients undergoing remission (261). Intriguingly, mTOR 
complexes can be inhibited by CD44 blockade (262), suggesting a dual role of CD44 
in adhesion as well as signal transduction during granuloma formation and 
persistence. Consistently reduced CD44 expression on LS CD4+ T cells may thus 
contribute to a higher tendency of these granulomas to spontaneously dissolve. 
Importantly, in Paper V, the organisation of tertiary lymphoid structures was 
found to differ between HLA-DRB1*03+ and HLA-DRB1*03- patients, with clusters 
of co-localised, proliferating T and B cells being more pronounced in HLA-
DRB1*03+ patients. Together, these data suggest that the entire granuloma ought 
to be a focal point of future studies, with the aim of delving deeper specifically 
into the lymphocytic compartment. As stated in the previous sections, rather than 
directing all efforts at individual cells, coverage of multiple cell types and cell-cell 
interaction would provide more comprehensive understanding of the 
immunological situation in the tissue. In addition, further investigation of CD44-
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mediated adhesion and/or signalling could prove valuable in identification of new 
prognostic markers, or even as a therapeutic target in progressive disease. 
 
4.2.5 Vimentin is a potential autoantigenic target of T and B cell-mediated 
inflammation in the lung 
In Paper I, the cytoskeletal protein vimentin was presented as a potential 
autoantigen, thanks to the ideal fit of a C-terminal peptide into the HLA-DRB1*03 
peptide-binding cleft, its repeated isolation from HLA-DR molecules on alveolar 
macrophages from sarcoidosis patients (116, 158), and the potential of said 
peptide to stimulate IFNγ production by T cells (117). This was further expanded 
on in Paper V, where vimentin-specific antibodies were identified in BALF of 
sarcoidosis patients and particularly HLA-DRB1*03+ individuals. The switch from 
vimentin N-terminal-specific antibodies in healthy individuals to C-terminal 
AVAs in HLA-DRB1*03+ sarcoidosis patients is particularly intriguing with regards 
to the previously identified peptide. Molecular modelling in Paper I showed that 
this peptide is likely to be recognised by Vα2.3+Vβ22+ CD4+ T cells when presented 
on HLA-DRB1*03, and in Paper V, the percentage of Vα2.3+Vβ22+ CD4+ T cells in 
BALF correlated with specific AVA production. Overlapping or partially 
overlapping T and B cell epitopes have been identified e.g. in coeliac disease (263), 
indicative of ongoing T-B cell interaction, which in Paper V could be observed as 
marked T-B co-localisation and proliferation in the inflamed tissue. Efficient 
antigen processing and presentation by B cells may contribute to activation and 
differentiation of T cells in and surrounding the granuloma, while T cell help to B 
cells in turn drives somatic hypermutation and affinity maturation, ultimately 
resulting in development of memory cells. 
 
In the context of sarcoidosis, it remains to be determined whether vimentin is a 
cause or effect of inflammation. Vimentin is known to be secreted from activated 
macrophages (264), which are abundant in the granulomatous environment, and 
Paper V verified that vimentin is readily available for uptake and processing in the 
lung. Its release could therefore be either a primary incident, following e.g. cell 
damage by intrusion of an external factor, or a secondary result of a triggering 
event driving granuloma formation and macrophage differentiation. In favour of 
vimentin being a primary antigen, Eberhardt and colleagues recently identified 
vimentin as a component of the Kveim reagent, and demonstrated a capacity of 
this vimentin to promote IFNγ production by T cells (157). Arguing against this are 
reports of anti-vimentin reactivity in other (auto)inflammatory conditions, such as 
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in lupus nephritis (163), RA (164) and IPF (265), suggesting that AVA reactivity is 
not disease-specific, but rather a sign of tissue autoimmunity, and possibly related 
to disease severity. This was exemplified by a weak, but detectable, association 
between reduced lung function and higher AVA titres in Paper V, similar to what 
was observed in IPF (265) and with kidney pathology in SLE (163). Alternatively, it 
is possible that anti-vimentin responses are a result of molecular mimicry 
following infection or exposure to environmental or occupational antigens. 
Further studies, such as are currently underway as a follow-up to Paper IV, are 
required to elucidate the true role of vimentin in sarcoidosis pathogenesis, but the 
results of this thesis at the very least suggest its involvement to be central to both 
T and B cell responses. CD4+ T cell reactivity to vimentin was also demonstrated in 
IPF patients (265), and although this study did not stratify for HLA type or which 
region of the protein was targeted, it could imply an autoimmune component of 
IPF, and conceivably a general involvement of vimentin in pulmonary 
inflammation. 
 
4.2.6 Functionally heterogeneous Vα2.3+Vβ22+ CD4+ T cells are key 
mediators of disease outcome 
The expansion of Vα2.3+Vβ22+ CD4+ T cells specifically in HLA-DRB1*03+ patients 
demonstrated in Papers I and IV implicates these cells as central to the process of 
antigen recognition. Papers I and II both delineated a high differentiation state of 
these cells, with high expression of CD69, T-bet, RORγT, CXCR3, CCR6, but not 
FoxP3 and only low levels of CD27. Previous studies on Vα2.3+ T cells, prior to the 
discovery of joint expression with Vβ22, have clearly demonstrated that this 
expansion, which ranges up to ten-fold during active disease, unfailingly 
normalises after clinical recovery (182). This is consistent with an antigen-specific 
response that ebbs out following antigen clearance. Interestingly, a less dramatic, 
but significant, expansion of Vα2.3+, but not Vα2.3+Vβ22+, CD4+ T cells was 
observed in patients negative for HLA-DRB1*03, but positive for HLA-DRB3*01. 
These two HLA molecules are similar in structure and function, and able to 
present a highly similar peptide antigen repertoire (266), suggesting that Vα2.3 is 
able to pair with different Vβ segments to recognise different antigenic peptides 
from the same (or different) proteins, or, alternatively, to execute different 
functions. Accordingly, molecular modelling in Paper I visualised the connection 
between TCR and HLA-DRB1*03 as primarily mediated by the Vα2.3 segment, 
while Vβ22 mainly interacted with Vα2.3, but also with the HLA-bound peptide. 
Moreover, Paper III revealed differential expression of co-stimulatory and/or  
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-inhibitory receptors in CD4+ T cells positive for either Vα2.3 alone or Vα2.3 and 
Vβ22, indicative of both effector and regulatory functions being performed in 
response to the same antigen. This is in line with the previous discussion of the 
immunological balance being maintained to a larger extent in HLA-DRB1*03+ 
patients, and suggests these TCR-specific cells to influence both sides of the scale. 
 
However, as carriage of HLA-DRB1*03 is most frequent in LS patients, who have a 
favourable prognosis, and LS is speculated to be an autoimmune condition, the 
intriguing – and seemingly contradictory – question remains as to how 
autoreactive cells can contribute to disease resolution. One hypothesis is that with 
an intracellular antigen such as vimentin, antigen-specific cells might aid in its 
clearance from the extracellular environment, where protein components may 
drive unwanted inflammatory reactions. Differentiated CD4+ T cells with the 
capacity to produce a broad range of cytokines and orchestrate a coordinated 
immune response could therefore cause an initially more intense reaction, 
represented by the acute symptomatic onset observed in LS, but also force 
resolution of granulomas and thereby disease. Along these lines, the T-B cell 
interaction demonstrated by Paper V would further suggest that AVAs may act to 
opsonise or neutralise extracellular vimentin, possibly participating in its removal. 
Consequently, in the absence of HLA-DRB1*03 and Vα2.3+Vβ22+ T cells, as in most 
non-LS patients, neither clearance nor immune regulation would be as efficient, 
resulting in prolonged IFNγ production, unrestricted cytotoxic CD8+ T cell activity 
and eventually irreversible tissue damage that may progress to pulmonary fibrosis 
(Fig. 17). While it is conceivable that a range in antigen specificity exists among 
patients with different disease manifestations, e.g. in terms of organ involvement, 
it appears as though presentation on other HLA molecules is less successful in 
induction of effector cell differentiation, regardless of the antigenic source. 
Instead, as observed by a more pronounced lymphocytosis on BALF differential 
count and higher levels of overall antibody production, it propagates a potent, but 
less antigen-focused, lymphocytic response in HLA-DRB1*03- patients. 
Nevertheless, despite the additional pieces of the sarcoidosis puzzle presented in 
this thesis, and the tools provided for further exploration of antigenic components 
that may drive inflammation, the true origin of disease remains a “blind spot” for 
future studies to shed light on.  
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5 CONCLUDING REMARKS 
The collective works of this thesis highlight the complexity of sarcoidosis 
immunology and the heterogeneity of disease, ranging from subtle molecular 
differences to markedly diverse clinical symptoms to contrasting prognostic 
indications. 
 
By using TCR-specific Vα2.3+Vβ22+ CD4+ T cells as a vehicle for antigen discovery 
studies, the papers presented delineate a critical role for these cells in antigen 
recognition, but also plausibly clearance, resulting in an active, but transient, 
inflammatory response. The high differentiation state of these cells, exemplified 
by expression of multiple transcription factors, chemokine receptors, activation 
and regulatory markers, coupled with the remarkable degree of clonality observed 
within and between patients positive for the HLA-DRB1*03 allele, are all strongly 
indicative of prolonged antigen exposure. Moreover, correlation of percentage of 
Vα2.3+Vβ22+ T cells with titres of specific antibodies suggest interaction between 
CD4+ T cells and B cells in the inflamed lung, a concept rarely explored in 
sarcoidosis and with potential implications for improved prognostic assessment. 
 
Clinically, LS and non-LS sarcoidosis are readily distinguished based on 
characteristic symptoms, but prediction of disease outcome is complicated by lack 
of ample knowledge of underlying immunological mechanisms. Furthermore, 
current therapeutic options are limited, unspecific and insufficient for managing 
the broad scope of symptoms. In this thesis, LS and non-LS are shown to harbour 
similar, but also significantly different immunological traits, which are likely to be 
instrumental in disease progression and outcome. The seemingly less aggressive, 
more antigen-driven, and more self-limiting immune response in LS relates well to 
the active inflammation and often spontaneous resolution observed in this patient 
group. Intriguingly, however, this disease form also exhibits features of 
autoimmunity, with selection for antigen-specific autoreactive T and B cells, as 
well as amplified levels of TH1/TH17 cells, frequently postulated to be central to 
pathogenesis in e.g. RA and MS. These findings emphasise immunological 
differences between organs, in turn suggesting that lessons learned from other 
diseases cannot be translated in their entirety to the sarcoid lung, and that further 
subclassification of patients is strongly warranted. Indeed, this would be of most 
benefit to non-LS patients, where prognosis is poorer and even less is known with 
regards to antigenic triggers. More comprehensive information on immunological 
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pathways will likely be essential in the ongoing effort to improve and personalise 
therapeutic strategies in sarcoidosis. 
 
In summary, this thesis constitutes a small but significant step forward in the 
search for disease-initiating antigens and the understanding of molecular 
pathways underlying different clinical phenotypes of pulmonary sarcoidosis. 
Hopefully, the results and theories presented here may in time contribute to the 
illumination, and ultimately dispersing, of the “blind spot” that is sarcoidosis 
aetiology. 
 
 
 
Figure 17 | Proposed mechanism of disease in LS and non-LS sarcoidosis. Graphic summary of 
the theorised immunological mechanisms in LS and non-LS, respectively, based on the findings 
presented in this thesis. The presence of a still unknown (self-)antigen in the pulmonary 
compartment triggers recognition and uptake by alveolar macrophages and DCs. In both disease 
forms, inability to completely clear the antigenic source results in its encapsulation and formation 
of characteristic granulomas. In LS, and particularly HLA-DRB1*03+ patients, TCR-specific CD4+ T 
cells are able to recognise peptide antigens and respond with a broad range of cytokine mediators. 
At the same time, these differentiated effector cells, expressing both T-bet and RORγT, appear able 
to restrict their own activity, as noted by maintained CD4+ T cell expression of regulatory receptors 
CTLA-4 and PD-1. CD4+ T cells in HLA-DRB1*03+ patients are further found to interact with B cells, 
giving rise to antigen-specific antibodies. Ultimately, an efficient antigen-driven T-B cell response 
contributes to spontaneous dissolution of granulomas and resolution of disease. In contrast, non-
LS CD4+ T cells demonstrate a more aggressive, TH1-dominant phenotype primarily expressing T-
bet and producing high levels of IFNγ. Moreover, higher expression of adhesion marker CD44 may 
contribute to granuloma persistence, while lack of regulatory capacity in CD4+ T cells allows for 
unrestrained CTL proliferation, resulting in tissue damage. B cell activation occurs in absence of 
GC formation, resulting in higher total Ig concentration but a lower degree of antigen specificity. 
Together, these processes of unspecific yet potent lymphocytic activity produce a state of chronic 
inflammation and tissue disruption, with a risk of developing permanent fibrotic scarring.  
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6 FUTURE PERSPECTIVES 
In the field of sarcoidosis, the primary aim of continued studies will be the search 
for, and identification of, disease-specific antigens. While current findings have 
described vimentin as a candidate target of both T cells and B cells in the lung, the 
involvement of vimentin in several other (auto)inflammatory conditions questions 
whether this is an occurrence specific for sarcoidosis or rather a tissue 
manifestation common to several chronic inflammatory conditions. Moreover, 
with regards to antigenic candidates, the inconclusive data presented over the past 
decades call for comprehensive, unbiased screening of possible peptide antigens 
recognised by the HLA-DRB1*03-TCR Vα2.3/Vβ22 complex, such as is now being 
performed in the next step of the study initiated in Paper I and continued in Paper 
IV. If successful, this approach could be further applied to other HLA-TCR 
combinations, e.g. in the context of HLA-DRB1*15 and chronic disease, or HLA-
DRB1*04 and ocular sarcoidosis. 
 
In addition, future studies should aim for more stringent and consistent 
subclassification of patients, not merely by LS and non-LS (which is, at present, 
rarely done outside Northern European countries), but also by HLA type, gender, 
presence of extrapulmonary symptoms and organ involvement. The disparity in 
symptomatic presentation between e.g. different ethnic groups, HLA backgrounds 
and genders indicate sarcoidosis to be not a single disease entity, but rather a 
spectrum of disorders, and proper classification of these conditions is essential for 
correct clinical management as well as for future research. Importantly, as 
indicated by the studies covered by this thesis, the traditional depiction of 
sarcoidosis as a solely CD4+ T cell- and mainly TH1-driven disease is no longer 
valid, and not only should regulatory features of T cells be further explored, but 
also the role of B cells, DCs and other tissue-resident immune cells with potential 
impact on antigen processing, presentation and downstream effector functions. 
 
Ultimately, the long-term goal of both antigen discovery and detailed 
immunological studies should be to improve diagnostic and especially prognostic 
procedures, create more precise and individualised therapeutic options, and if 
possible, to develop preventive measures. For this reason, understanding not only 
the cause of disease, which may well differ between LS and non-LS, and within the 
non-LS group, but also the immunological response to this initial pathogenic 
event is critical. Importantly, data gathered from human samples offer a mere 
snapshot of a complex disease course, and must therefore be treated as such. As 
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exemplified by these and preceding studies, the cellular composition in the lung 
markedly differs from that of peripheral blood, wherewith sampling from the 
periphery is insufficient for proper assessment of the present immunological state 
of the patient. Despite the invasive nature of bronchoscopy, repeated 
investigations during follow-up and after clinical remission would be highly 
desirable from a research perspective, and provide information that could prove 
essential in unravelling the mechanisms that govern disease resolution and 
progression. Furthermore, systematic exploration into the affected tissue should 
be prioritised in order to gain insight into differences in granuloma formation and 
persistence between clinical phenotypes, which may be beneficial in the 
development of new treatments.
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